



**HAL**  
open science

## **Pneumococcus uses COMMD2 to alter host cellular immunity**

Michael Connor, Lisa Sanchez, Christine Chevalier, Tiphaine Camarasa, Filipe Carvalho, Matthew J.G. Eldridge, Thibault Chaze, Mariette Matondo, Esma Karkeni, Sara Dufour, et al.

### ► **To cite this version:**

Michael Connor, Lisa Sanchez, Christine Chevalier, Tiphaine Camarasa, Filipe Carvalho, et al.. Pneumococcus uses COMMD2 to alter host cellular immunity. 2026. <hal-05447592>

**HAL Id: hal-05447592**

**<https://hal.science/hal-05447592v1>**

Preprint submitted on 7 Jan 2026

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Copyright - All rights reserved

1 **Title:**

2 Pneumococcus uses COMMD2 to alter host cellular immunity.

3

4 **Authors:** Michael G. Connor<sup>1\*</sup>, Lisa Sanchez<sup>2</sup>, Christine Chevalier<sup>1</sup>, Tiphaine M. N. Camarasa<sup>1</sup>, Filipe  
5 Carvalho<sup>3</sup>, Matthew J.G. Eldridge<sup>1</sup>, Thibault Chaze<sup>4</sup>, Mariette Matondo<sup>4</sup>, Esma Karkeni<sup>5</sup>, Sara Dufour<sup>6</sup>,  
6 Francis Impens<sup>6</sup>, Sebastian Baumgarten<sup>7</sup>, Jost Enninga<sup>2</sup>, Melanie A. Hamon<sup>1\*</sup>.

7

8 **Affiliations:**

9 1 Chromatin and Infection, Institut Pasteur, Paris, France.

10 2 Dynamics of Host–Pathogen Interactions Unit, Institut Pasteur, & UMR CNRS, Paris, France.

11 3 Institut MICALIS (UMR 1319) INRAE, AgroParisTech, Université Paris-Saclay

12 4 Institut Pasteur, Université de Paris Cité, CNRS UAR2024, Proteomics Platform, Mass Spectrometry  
13 for Biology Unit, 75015 Paris, France.

14 5 Single Cell Biomarkers UTechS, Institut Pasteur, Université Paris Cité, Paris, France.

15 6 VIB-UGent Center for Medical Biotechnology, VIB Proteomics Core, VIB, Department for  
16 Biomolecular Medicine, Ghent University, Ghent, Belgium.

17 7 Institut Pasteur, Université Paris Cité, Parasite RNA Biology, F-75015 Paris, France

18

19

20 \*Correspondence:

21 Michael G. Connor (mconnor@pasteur.fr) & Melanie A. Hamon (melanie.hamon@pasteur.fr)

22

23 **Abstract:**

24 NF- $\kappa$ B driven cellular immunity is essential for both pro- and anti-inflammatory responses to  
25 microbes, which makes it one of the most frequently targeted pathways by bacteria during  
26 pathogenesis. How NF- $\kappa$ B tunes the epithelial response to *Streptococcus pneumoniae* across the  
27 spectrum of commensal to pathogenic outcomes is not fully understood. In this study, we compare a  
28 commensal-like 6B ST90 strain to an invasive TIGR4 isolate and demonstrate, through comparative  
29 mass spectrometry of the p65 interactome, TIGR4 challenge triggers a novel interaction of COMMD2  
30 with p65 and p62. Mechanistically, we show this complex mediates export of p65 for degradation and  
31 COMMD2 is necessary for altering host cellular immunity. With these results, we reveal for the first  
32 time a new bacterial pathogenesis mechanism to repress host inflammatory response through  
33 COMMD2 and p65 degradation while presenting a paradigm for diverging NF- $\kappa$ B responses to  
34 pneumococcus.

35

36 **Introduction:**

37 Airway epithelial cells, which line the entirety of the human respiratory tract, play a key role  
38 in both driving and shaping the host inflammatory and homeostatic response(s) to both pathogenic  
39 and commensal microbes<sup>1-3</sup>. Indeed, defining molecular processes of bacterial-host crosstalk at this  
40 interface has emerged as a key determinant shaping how bacterial pathobionts escape from  
41 asymptomatic carriage within the human upper respiratory tract (URT) to become pathological agents  
42 causing symptomatic disease. In fact, for human restricted pathobionts, such as *Streptococcus*  
43 *pneumoniae* (the pneumococcus), *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Staphylococcus*  
44 *aureus*, colonization of the human URT is critical for maintenance of their natural reservoir and a  
45 prerequisite for potentially lethal disease<sup>4,5</sup>. Yet mechanistic understanding of the cellular processes  
46 involved in compartmentalizing commensal-like versus pathogenic host outcomes to these  
47 pathobionts remains unclear.

48 We previously showed that isolates of *Streptococcus pneumoniae* drive differential host  
49 responses by fine tuning airway epithelia cellular immunity<sup>6-12</sup>. A commensal-like serotype 6B ST90  
50 CC156 lineage F isolate, in contrast to an invasive favoring TIGR4 isolate, triggered a unique NF- $\kappa$ B  
51 signature through the chromatin remodeler KDM6B, that was required for host mediated confinement  
52 to the upper respiratory tract in a murine infection model. Surprisingly, these studies also revealed  
53 that the pathogenic *S. pneumoniae* strain TIGR4 largely suppressed NF- $\kappa$ B activation and downstream  
54 gene transcription<sup>6</sup>. As the eukaryotic NF- $\kappa$ B family of transcriptional regulators are well documented  
55 for their potent ability to drive both pro- and anti-inflammatory cellular immune responses during  
56 microbe-host interaction, we sought to better define this dichotomy<sup>13-15</sup>.

57 To date, a large majority of bacterial virulence phenotypes either co-opt NF- $\kappa$ B repressors or  
58 directly target NF- $\kappa$ B pathway components using virulence factors (general review<sup>15,16</sup>). Generally,  
59 upon sensing of inflammatory molecules, such as cytokines (IL-1 $\beta$  or TNF $\alpha$ ), pathogen-associated  
60 molecular patterns (PAMPs; i.e. lipopolysaccharide), or danger-associated molecular patterns  
61 (DAMPs; i.e. IL-1 $\alpha$  or nuclear protein HMGB1), NF- $\kappa$ B subunits are rapidly activated by phosphorylation  
62 on serine residues (S536 and S276). Simultaneously, NF- $\kappa$ B dimers are released from their inhibitory  
63 I $\kappa$ B proteins and translocated to the nucleus for additional modification. Ultimately, this process leads  
64 to the binding of activated dimers to cognate NF- $\kappa$ B DNA motifs, thereby inducing NF- $\kappa$ B dependent  
65 gene transcription. NF- $\kappa$ B activation is tightly controlled for precise and rapid induction, but also for  
66 prompt repression. NF- $\kappa$ B dimers can be repressed through extraction, sequestration, and  
67 degradation from within the nucleus, while in parallel blocking cytoplasmic activation and promoting  
68 transcription of negative regulators<sup>17,18,20,22-26</sup>. However, in contrast to the myriad of studies on  
69 activators only a few negative regulators of NF- $\kappa$ B and their pathways have been documented.

70 COMMD (copper metabolism gene MURR1 domain)<sup>27</sup> proteins are among the select few  
71 known negative regulators of NF- $\kappa$ B<sup>25,27-32</sup>. There are ten members of the COMMD family, all of which,  
72 interact with NF- $\kappa$ B to regulate signaling. The best-studied archetype member, COMMD1, upon  
73 stimulation by TNF will lead to extraction of p65 from chromatin, followed by ubiquitination and

74 proteasomal degradation. This process functions independently of NF- $\kappa$ B nuclear translocation and  
75 I $\kappa$ B $\alpha$ , but through association with Cullin proteins, is able to terminate NF- $\kappa$ B signaling<sup>25,27,29-35</sup>. For the  
76 other COMMD proteins, however, neither their functional activity, their mechanism of NF- $\kappa$ B  
77 repression, or their interacting partners, outside of cullins, are known.

78 Here, we demonstrate that a pathogenic TIGR4 pneumococcal strain<sup>6</sup>, in contrast to a  
79 commensal-like 6B ST90 isolate<sup>6</sup>, represses phosphorylation and activation of NF- $\kappa$ B p65. In fact,  
80 TIGR4 infection leads to specific degradation of p65 in airway epithelial cells, even upon stimulation  
81 with a strong inflammatory agonist, IL-1 $\beta$ . We performed an interactome of p65 and show that each  
82 pneumococcal strain interacts with diverging p65 interacting partners, revealing an original  
83 aggrephagy mechanism involving COMMD2 and p62. Furthermore, our studies on the understudied  
84 functionality of COMMD2 by RNAi demonstrated it is necessary in regulating host cellular immunity  
85 both basally and during pneumococcal challenge. Finally, deeper investigation of the COMMD2  
86 interactome in comparison to the 6B ST90 isolate and under stimulation with the potent pro-  
87 inflammatory cytokine IL-1 $\beta$  revealed further specificity during TIGR4 challenge, with its COMMD2  
88 interactome enriching for additional transcriptional and translational components. Altogether, we  
89 report a novel mechanism of pathogenesis to degrade p65 and repress the host response that is  
90 specifically induced by TIGR4.

91

## 92 **Results:**

### 93 TIGR4 engages a divergent NF- $\kappa$ B p65 interactome in comparison to commensal-like 6B ST90.

94 We previously showed that TIGR4, in comparison to 6B ST90 (hereafter 6B), induced a  
95 transcriptionally different NF- $\kappa$ B dependent response, which was largely associated with gene  
96 repression<sup>6</sup>. To understand NF- $\kappa$ B p65 activation differences between the invasive TIGR4 and  
97 commensal-like 6B pneumococcal isolates we performed mass spectrometry of NF- $\kappa$ B p65 (Fig. 1A).  
98 An A549 GFP-p65 cell line was challenged with either TIGR4 or 6B and 2 hrs post-challenge GFP-p65  
99 was immunoprecipitated with a matched A549 GFP alone control for mass spectrometry interactome  
100 analysis along with p65 posttranslational modifications (Fig. 1B; Sup. Table 1).

101 Analysis of the individual TIGR4 and 6B volcano plots in comparison to GFP alone showed  
102 specific enrichment for known NF- $\kappa$ B p65 associated partners (blue), reflecting the robustness of our  
103 A549 GFP-p65 cell line (Fig. 1C & D). GO ontology analysis of these individual p65 interactomes to GFP  
104 alone showed TIGR4 enriched for cellular trafficking components along with p62/SQSTM1 (Fig. 1C;  
105 Sup. Fig 1A), whereas the interactome of 6B reflected enrichment for classical NF- $\kappa$ B signaling  
106 components and signaling processes (Fig. 1D; Sup. Fig 1B). While the overall interactomes of TIGR4  
107 and 6B appear similar, deeper investigation revealed key differences. This agrees with our previous  
108 findings demonstrating fine-tuning of NF- $\kappa$ B p65 signatures between TIGR4 and 6B was essential for  
109 commensal-like vs. invasive host responses<sup>6</sup>.

110 However, to directly investigate any divergent p65 interactors between the TIGR4 and 6B  
111 datasets we compared the interactomes against each other (Fig. 1E). This comparison showed lower  
112 overall association of known NF- $\kappa$ B partners for TIGR4 alongside significant specific enrichment for  
113 COMMD proteins (2 & 4) and proteins associated with degradation/ubiquitin pathways (HDAC6,  
114 UBE2C...) by GO ontology (Fig. 1E & F; Sup. Table 1)<sup>36</sup>.

115 Indeed, p62 and HDAC6 are classical mediators of aggrephagy, which is a form of selective  
116 autophagy to degrade protein aggregates<sup>36-38</sup>. Interestingly, it has also been shown that abnormal NF-  
117  $\kappa$ B p65 activation may be a signal p62 mediated turnover<sup>39</sup>. Moreover, COMMD proteins, such as  
118 COMMD2, are known to negatively regulate NF- $\kappa$ B family members through degradation<sup>27,29,30,34,35,40</sup>.  
119 Of the two COMMD proteins found in our TIGR4 dataset, COMMD2 was previously shown, by ectopic  
120 expression, to reside in the cell cytosol and had a higher association with RelA and NF- $\kappa$ B1<sup>27,35</sup>.  
121 Therefore, our proteomic data suggested that p65 could be targeted for degradation through an  
122 aggrephagy pathway under TIGR4 infection conditions.

123

### 124 TIGR4 differentially engages NF- $\kappa$ B p65 in comparison to commensal-like 6B ST90.

125 Previously, we clearly showed commensal-like 6B pneumococcal strain activates p65 to drive a unique  
126 inflammatory signature in comparison to a disease causing TIGR4 strain<sup>6,41</sup>. Interestingly, this was also  
127 seen in kinetic NF- $\kappa$ B dependent gene expression profiles when comparing TIGR4 to 6B and a positive  
128 control IL-1 $\beta$ <sup>6,41</sup>. Given our previous findings and the mass spectrometry data showing enrichment for  
129 aggrephagy, we hypothesize that TIGR4 disrupted NF- $\kappa$ B activation. To directly test the NF- $\kappa$ B  
130 activation hypothesis, we challenged A549 cells with either TIGR4 or 6B ST90 alone, or in combination  
131 with IL-1 $\beta$ , a pro-inflammatory stimulus known to induce p65 phosphorylation of key serine residues  
132 536 and 276 (review<sup>23</sup>). Cells were collected 2hr post-challenge for immunoblotting to determine the  
133 total levels of p65 and phosphorylated p65. The ratio of phos-S536 to total p65 between TIGR4 and  
134 6B ( $\pm$  IL-1 $\beta$ ) against the IL-1 $\beta$  control showed decreased levels, whereas the ratio of phos-S276 to total  
135 p65 showed minimal differences (Fig. 2A – C). Curiously, for all TIGR4 challenge groups total level of  
136 p65 was significantly reduced ( $p \leq 0.01$ ) compared to uninfected, IL-1 $\beta$  or 6B exposed cells (Fig. 2B).  
137 Thus, we compared phosphorylated p65 S536 and S276 to actin in order to determine whether TIGR4  
138 challenge reduced their total cellular pool. Indeed, from this analysis it was clear that TIGR4 in  
139 comparison to 6B, reduced the total cellular amount of S536 p65 and not S276 (Sup. Fig. 2 A & B).  
140 Moreover, through cross-comparison between TIGR4 and 6B ( $\pm$  IL-1 $\beta$ ) a trend emerged that either  
141 TIGR4 condition reduced total p65 S536 or S276 amounts, with the most substantial difference being  
142 on levels of p65 S536 (Sup. Fig. 2 A & B). Next, we tested whether TIGR4 challenge also lowered the  
143 level of p65 S536 phosphorylation in primary human nasal epithelial cells, since *S. pneumoniae* is an  
144 opportunistic respiratory pathogen that primarily colonizes first the upper airway epithelial cells. Our  
145 results showed a comparable trend for TIGR4 ( $\pm$  IL-1 $\beta$ ) in comparison to uninfected, IL-1 $\beta$  or 6B.  
146 Importantly in TIGR4 lysates the total levels of p65, S536 and S276 were decreased in comparison to  
147 uninfected, IL-1 $\beta$  and 6B groups (Sup. Fig. 2C). Altogether, these data clearly indicated that TIGR4  
148 challenge reduced total amounts of p65, phos-S536 and phos-S276, which primarily affected the ratio  
149 of phos-S536 to total p65, and aligned well with the interactome data.

150 As p65 phos-S536 is a marker reflecting p65 nuclear translocation (review<sup>23</sup>), our observations  
151 that TIGR4 challenge resulted in significant difference in the S536 / p65 ratio raised the possibility that  
152 TIGR4 challenge induced differential nuclear localization kinetics in comparison to 6B. To assess this  
153 we completed time course microscopy of A549 cells to evaluate nuclear S536 levels by  
154 immunofluorescence, as this reflects p65 translocation post liberation from the cytoplasmic NEMO  
155 complex (review<sup>23</sup>). For this, we segmented on cellular nuclei (Draq5) and quantified nuclear p65 S536  
156 intensity (Fig. 2E & F). Our kinetics show nuclear S536 profile between TIGR4 and 6B differs. TIGR4  
157 leads to a slow and modest increase starting at 10 minutes and peaks at 90 mins before coming back  
158 down. In contrast 6B kinetics mirror the positive control, IL-1 $\beta$ , with a rapid increase by 10 minutes  
159 followed by a gradual decline (Fig. 2E & F). When A549 are challenged with either TIGR4 or 6B in  
160 combination with IL-1 $\beta$ , the levels of nuclear S536 increase rapidly for both, similarly to IL-1 $\beta$  alone.  
161 These data supported differences observed by immunoblot, whilst suggesting that TIGR4 ( $\pm$  IL-1 $\beta$ ) was  
162 triggering aberrant and low level p65 activation in comparison to IL-1 $\beta$  and 6B.

163 Since we previously showed that TIGR4 alone, in comparison to 6B and IL-1 $\beta$ , drove minimal  
164 NF- $\kappa$ B p65 dependent gene expression kinetically<sup>6,41</sup>, we tested if IL-1 $\beta$  at the time of challenge could  
165 restore expression profiles to TIGR4. Total RNA was periodically collected from A549 cells out to 120  
166 minutes post challenge with TIGR4 ( $\pm$  IL-1 $\beta$ ) and IL-1 $\beta$  alone. Relative expression was determined for  
167 CFS2 and PTGS2 (COX-2) against uninfected/untreated controls at each time point. TIGR4 in  
168 comparison with IL-1 $\beta$  alone did not lead to activation of any of the genes out to 2h post challenge,  
169 which aligns with our previous findings<sup>6</sup> (Sup. Fig. 2D & E). Furthermore, under conditions where IL-  
170 1 $\beta$  was added during TIGR4 challenge, there was both a delay and a repression of these transcripts in  
171 comparison to IL-1 $\beta$  alone.

172 Transcriptional activation by p65 requires its binding to cognate kappa-binding sites at the  
173 chromatin level. Therefore, we evaluated levels of chromatin bound p65 at the locus of the NF- $\kappa$ B  
174 dependent gene *PTGS2* and *CSF2* as these two genes had striking transcriptional profiles. Chromatin  
175 was collected from A549 cells 2 hrs post-challenge with TIGR4 ( $\pm$  IL-1 $\beta$ ) and the recovery of p65

176 quantified against uninfected and IL-1 $\beta$  controls by ChIP-qPCR targeting kappa-binding sites upstream  
177 of the *PTGS2* and *CSF2* transcriptional start site (Sup. Fig. 2F - H). For both genes TIGR4 challenged  
178 cells resulted in less than 5% recovery of p65. This stands in contrast to the three-fold higher p65  
179 recovery in IL-1 $\beta$  alone (Sup. Fig. 2G & H). Interestingly, in the TIGR4 + IL-1 $\beta$  condition p65 recovery  
180 was comparable to IL-1 $\beta$  alone (Sup. Fig. 2G & H). Therefore, the lack of p65 driven transcription under  
181 TIGR4 challenge is intrinsically due to the absence of p65 at the chromatin. Altogether, these results,  
182 in combination with our previous findings, show that TIGR4, in contrast to the IL-1 $\beta$ , is driving  
183 dysfunctional p65 signaling<sup>6,41</sup>.

184

#### 185 Blocking autophagy increases cytoplasmic COMMD2, p62 and p65 levels.

186 To study the localization of COMMD2, we generated a COMMD2 cell line. Strikingly, upon  
187 TIGR4 challenge of the GFP-COMMD2, we observed by microscopy that TIGR4 drove COMMD2  
188 localization to the nucleus. COMMD2 is an otherwise cytoplasmic protein containing two nuclear  
189 export signals<sup>34,35,43</sup>. We confirmed this translocation by immunoblotting GFP-COMMD2 cell  
190 fractionations obtained from cells challenged with TIGR4 ( $\pm$  IL-1 $\beta$ ) alongside from uninfected and IL-  
191 1 $\beta$  controls (Sup. Fig. 3A – C). Cells treated with IL-1 $\beta$  or uninfected had 20% COMMD2 in the nucleus,  
192 in contrast to that of TIGR4 ( $\pm$  IL-1 $\beta$ ) which showed 80% of COMMD2 was nuclear (Sup. Fig. 3B). Finally,  
193 we tested if the commensal-like strain 6B ST90 could also induce COMMD2 nuclear localization.  
194 Immunoblotting of cell fractions of the GFP-COMMD2 we show 6B ST90 was incapable of triggering  
195 nuclear localization of COMMD2 (Sup. Fig. 3C). Thus, these data demonstrate TIGR4 specifically  
196 triggers COMMD2 nuclear localization.

197 Using the COMMD2 cell line, we tested the effect of blocking autophagy with Bafilomycin A1  
198 on the levels of p65, p62 and COMMD2, 2 hrs post-challenge with either IL-1 $\beta$  or TIGR4 ( $\pm$  IL-1 $\beta$ ; MOI  
199 20) using confocal microscopy (Fig. 3A – F; rep. images Sup. Fig. 4 p65 & Sup. Fig. 5 p62). Baf. A1  
200 treatment had minimal effect on total or nuclear COMMD2 for uninfected and IL-1 $\beta$ , whereas TIGR4  
201 ( $\pm$  IL-1 $\beta$ ) stimulation significantly ( $pV \leq 0.001$ ) increased total COMMD2 (Fig. 3 A & B). Interestingly,  
202 there was a slight inverse decrease in TIGR4 ( $\pm$  IL-1 $\beta$ ) nuclear COMMD2 – strongly supporting a role  
203 for autophagy in cytoplasmic turnover. Similarly to COMMD2, TIGR4 ( $\pm$  IL-1 $\beta$ ) challenged cells treated  
204 with Baf. A1 displayed an increase in p62, and restored p65 levels comparable to uninfected controls  
205 (Fig. 3C - F). Moreover, in Baf. A1 treated cells challenged with TIGR4 the area of p65 and p62 puncta  
206 increased, which is a conventional phenotype associated with blocked autophagosomes (Fig. 3G & H;  
207 rep. images Sup. Fig. 4 p65 & Sup. Fig. 5 p62).

208 Overall, the combination of these data clearly shows TIGR4 challenge of airway epithelial cells  
209 specifically led to COMMD2 nuclear localization and autophagy, a largely cytoplasmic process,  
210 contributing to reduce the levels of p65 and COMMD2 within the cell.

211

#### 212 COMMD2 is associated with both p65 and p62.

213 To further test the autophagy hypothesis, we wanted to determine whether COMMD2, p65  
214 and p62 formed a complex; thus, a plausible explanation why blocking autophagy with Baf. A1 would  
215 increase all three of these components. Currently, the only commercial COMMD2 antibody has limited  
216 suitability for immunoprecipitation or immunofluorescence, thus, we used the GFP-COMMD2 cell line.  
217 For this we challenged cells with either 6B ST90 ( $\pm$  IL-1 $\beta$ ), TIGR4 ( $\pm$  IL-1 $\beta$ ) or IL-1 $\beta$  controls for 2h and  
218 performed immunoprecipitation of GFP-COMMD2 from cell lysates. Samples were probed for p65 or  
219 p62 to detect interaction with COMMD2. Our results show that only under TIGR4 challenge conditions  
220 do p65 and p62 interact with COMMD2 (Fig. 4A & B). Furthermore, upon addition of IL-1 $\beta$ , p65  
221 interacts with COMMD2 to even higher levels.

222 To evaluate complex formation in primary cells, we collected lysates from primary nasal cells  
223 challenged with either TIGR4 or 6B, as well as from uninfected controls. We performed p65  
224 immunoprecipitation and tested whether TIGR4 could drive an endogenous native interaction of p65  
225 with COMMD2 (Sup. Fig. 6A). Samples were probed for p65 and COMMD2 prior to being revealed with  
226 the VeriBlot secondary HRP antibody. This secondary HRP antibody does not recognize denatured

227 heavy and light chain IgG, which would otherwise occur closely to our targets potentially masking  
228 positive bands (65kda & 25kda). Our results showed a 4-fold increase in COMMD2 interaction with  
229 p65 under TIGR4 challenge (Sup. Fig. 6B). However, there was a significant reduction of the detected  
230 levels of COMMD2 and p65 under TIGR4 conditions in comparison to uninfected or 6B (Sup. Fig. 6C  
231 & D). This is consistent with results shown above and degradation of COMMD2 and p65 by aggrephagy.  
232 Interestingly, there was a weight shift of COMMD2 in the p65 IP, suggestive of posttranslational  
233 modification – known to occur on COMMD proteins. Therefore, COMMD2 is a new TIGR4 induced  
234 interacting partner of p65 and is a component of a p65-COMMD2-p62 complex.

235

#### 236 COMMD2 exports p65 for lysosomal degradation.

237 It is known that the archetype COMMD family member, COMMD1, undergoes  
238 nucleocytoplasmic trafficking<sup>25,35,42</sup>. Given that aggrephagy primarily occurs in the cellular cytosol, we  
239 reasoned that aberrantly phosphorylated p65 during TIGR4 challenge led to nuclear translocation of  
240 COMMD2, which in turn was involved with facilitating nuclear export of these p65 complexes.

241 Therefore, we tested whether COMMD2 was exported through CRM1 by using the  
242 Leptomycin B inhibitor<sup>43</sup>. GFP-COMMD2 cells were treated with Leptomycin B (10 nM) prior to  
243 immunofluorescence imaging of p62 and p65. Strikingly, blocking nuclear export resulted in  
244 COMMD2, p62 and p65 now becoming localized to the nucleus even in uninfected and IL-1 $\beta$  treated  
245 cells. In fact, COMMD2 and p62 were detected within nuclear puncta (Fig. 5A) where p65 was located  
246 (Fig. 5B). Notably, our IL-1 $\beta$  positive pro-inflammatory stimulus control, known to drive nuclear  
247 translocation of p65, had a significant ( $pV \leq 0.0001$ ) increase in the nuclear level of COMMD2 and p62  
248 in comparison to treated cells (Fig. 5C & D). These surprising data suggest that under nuclear export  
249 blockage, which occurs with Leptomycin B treatment<sup>43</sup>, COMMD2 and p62 are naturally recruited to  
250 the nucleus at specific puncta through a defined process.

251 Interestingly, upon challenge with TIGR4, Leptomycin B treated cells displayed higher levels  
252 of COMMD2 and p62 accumulation in the nucleus than without treatment (Fig. 5A, C & D). Thus, upon  
253 inhibiting nuclear export of COMMD2 and p62, these proteins are no longer degraded upon infection  
254 and accumulate in the nucleus. Although COMMD2 and p62 puncta are observed upon addition of  
255 Leptomycin B, the substantial amount of p65 trapped within the nucleus of these cells rendered  
256 definitive scoring of puncta and colocalization for both difficult. Due to this, we measured a tangent  
257 line (20  $\mu$ m) across observed local maxima intensity “spots” to overlay the traces of p62 and p65 with  
258 COMMD2 in uninfected, IL-1 $\beta$  and TIGR4 conditions demonstrating that indeed p62 and p65  
259 associated with COMMD2 (Fig. 5C & D). Quantification of the total nuclear COMMD2 intensity  
260 however showed inhibition of CRM1 did not increase total levels in comparison to untreated across  
261 all groups (Fig. 5E). Thus, Leptomycin B inhibition led to concentrated accumulation of COMMD2 into  
262 puncta. In contrast, Leptomycin B inhibition increased both p62 and p65 nuclear levels in all conditions  
263 compared to untreated cells (Fig. 5F & G). Furthermore, under conditions of TIGR4 + IL-1 $\beta$  and  
264 Leptomycin B inhibition, we observed a significant ( $pV \leq 0.0001$ ) increase in p62 puncta compared to  
265 TIGR4 alone (Sup. Fig. 7A & B). These data show that TIGR4 challenge leads to an active CRM1  
266 dependent export of p65 and the COMMD2 complex.

267

#### 268 The TIGR4 COMMD2 interactome is unique and enriched for NF- $\kappa$ B associated partners.

269 Our results to this point clearly show the role of COMMD2–p65 during TIGR4 bacterial  
270 challenge is unique even with respect to IL-1 $\beta$ . However, to date knowledge of COMMD protein  
271 interacting partners and biological roles are largely centered around their interactions with NF- $\kappa$ B  
272 subunits and cellular processes of trafficking, proteasome degradation and transcription<sup>25,31,44,45</sup>, with  
273 limited understanding of their potential mechanisms or impact during bacterial infection.

274 To deepen our investigation of TIGR4 induced COMMD2-p65 interaction and better define a  
275 biological role for it during bacterial challenge, we assessed the COMMD2 interactome by mass  
276 spectrometry (Fig. 6A-D). For this we immunoprecipitated GFP-COMMD2 from A549 cells 2 hrs post-  
277 challenge with either TIGR4, 6B ST90 or our positive inflammatory control IL-1 $\beta$  for comparison against

278 uninfected. Pointedly in this mass spectrometry study we used the cross-comparison of GFP-COMMD2  
279 against GFP alone to control for both non-specific COMMD2 complexes and artifacts which may be  
280 intrinsic to ectopic expression (Sup. Fig. 8A; Sup. Table 2). The results of this comparison identified  
281 known COMMD2 associations with other COMMD proteins, Commander and Retriever complexes  
282 (CCDC22, CDC93, VPS35L, COMMD6, COMMD2, COMMD1, COMMD4, COMMD8, COMMD9,  
283 COMMD3 & VPS29)<sup>46</sup>, which further strengthens the robustness of our approach.

284 In contrast to 6B and IL-1 $\beta$  volcano plots, TIGR4 prompted positive enrichment for p65 (RelA),  
285 p62 (SQSTM1) and HDAC6, which is another aggrephagy associated protein (Fig. 6B-C). Notably, for IL-  
286 1 $\beta$ , the volcano plot shows none of the significant partners of COMMD2 held any known NF- $\kappa$ B  
287 association (via BioGRID) at 2hrs (Fig. 6D). Moreover, there was a 5- and 80-fold higher recovery of  
288 significantly enriched interacting partners under the TIGR4 condition compared to 6B ST90 and IL-1 $\beta$   
289 respectively (Fig. 6B-D; Sup. Table 3). Cross comparing these targets, we discovered that 254 unique  
290 proteins were associated with COMMD2 under TIGR4 challenge with 92 of them being also found in  
291 our p65 interactome dataset (Fig. 6E; Sup. Table 1). Remarkably overall this unique comparison of the  
292 COMMD2 interactome datasets clearly supported the specificity of COMMD2 – p65 (RelA) during  
293 TIGR4 challenge.

294 Finally, analysis using Panther ontology protein class of the significant targets obtained from  
295 the interactome underscored a unique TIGR4 enrichment for host metabolite and protein modifying  
296 enzymes as well as proteins associated with translation (Fig. 6F). From the analysis we also identified  
297 a putative COMMD2 posttranslational modification associated with ubiquitination at Lysine residue  
298 50 (Sup. Table 2), which aligns with our previous endogenous co-immunoprecipitation of COMMD2-  
299 p65 (Sup. Fig. 6A). Altogether, these results showed during TIGR4 challenge COMMD2 function was  
300 specific with a potential role in host inflammatory response.

301

### 302 COMMD2 is a selective negative regulator of host cellular immunity.

303 Having previously shown TIGR4 directly represses host transcription and in particularly NF- $\kappa$ B  
304 dependent targets<sup>6,41</sup>, we speculated that COMMD2 was required to alter NF- $\kappa$ B p65 driven host  
305 immunity upon stimulation with TIGR4. Thus, inhibiting COMMD2 would lead to increased cytokine  
306 production. To our knowledge, no direct chemical inhibitors of COMMD2 exist, so we used RNAi to  
307 knockdown COMMD2 and p62 in primary human nasal epithelial cells (Sup. Fig. 9A-C). Whereas both  
308 siRNAs to COMMD2 or their mixture resulted in 50-60% reduction, a single siRNA to p62 reduced the  
309 target >70% (Sup. Fig. 9C). While knockdown of COMMD2 was not ideal it was consistently greater  
310 with the second siRNA, thus we proceeded with bacterial challenge suspecting this minimal reduction  
311 in COMMD2, in comparison to scrambled or p62, would be enough to discern roles for COMMD2  
312 and/or p62 upon the analytes within our Luminex panel.

313 Following 48hrs of either Scrambled (Scr), COMMD2 or p62 RNAi primary human nasal cells  
314 were challenged for 4 hrs with either IL-1 $\beta$ , TIGR4 or 6B ( $\pm$  IL-1 $\beta$ ), with post-challenge supernatants  
315 collected for Luminex (27-plex; COMMD2 Fig. 7A; Scr Sup. Fig. 9D; p62 Sup. Fig. 9E). Strikingly  
316 COMMD2 RNAi resulted in selective elevation of multiple targets, even in the uninfected group, with  
317 several being significantly higher than their respected scr control (pV reported; Fig. 7A). These analytes  
318 - CCL20, CXCL1, CXCL10, IL-1ra, IL-8 and PTX3 - either border or were significantly different with  
319 respect to each sample scr control. Interestingly, CCL20, CXCL1, CXCL10, IL-1ra, and IL-8 were also  
320 elevated in the p62 RNAi data (Sup. Fig. 9E). Given this surprising result, we determined whether  
321 COMMD2 RNAi impacted uninfected, IL-1 $\beta$ , TIGR4 or 6B equally. For this we first compared the  
322 absolute difference of COMMD2 RNAi to scr (Fig. 7B). Our results showed that while on average TIGR4  
323 challenge of COMMD2 RNAi cells increased all 27 analytes in comparison to 6B and uninfected cells  
324 these elevated levels remained comparable to the IL-1 $\beta$  treated control. However, to assess the  
325 degree in which COMMD2 or p62 RNAi affected TIGR4 or 6B we compared each RNAi condition to the  
326 scr control (Fig. 7B). This comparison clearly showed knockdown of COMMD2 and p62 during TIGR4  
327 challenge had far more impact on the profiles of the 27 analyte examined than for 6B. Altogether,  
328 these data show that: 1) COMMD2, and likely p62, have a role in regulating specific cellular immunity

329 molecules in uninfected cells, and 2) TIGR4 relies on both COMMD2 and p62 to alter secreted host  
330 immunity analytes.

331 Due to this, we explored whether a commonality existed in predicted NF- $\kappa$ B p65 (RelA) binding  
332 motifs among these targets transcriptional start site (TSS). Herein, we pulled  $\pm$  2kb surrounding the  
333 gene TSS (UCSC genome browser) for Transcription factor Affinity Prediction (TRAP) analysis<sup>47</sup> and for  
334 comparison of the NF- $\kappa$ B motif to the canonical motif (JASPAR). Mapping predicted NF- $\kappa$ B motifs from  
335 the COMMD2 targets did reveal several. However, there was no apparent commonality in location or  
336 binding affinity of these predicted motif sites in this small dataset (Fig. 7C). However, the NF- $\kappa$ B motif  
337 consensus sequence of the small COMMD2 targets, in comparison to the canonical motif using  
338 Weblogo<sup>48</sup>, showed a subtle change with higher probability of G/A (pos. 3) and C/T (pos. 7; Fig. 7D).  
339 Interestingly, p62 RNAi also resulted in selective elevation of CCL20, CXCL1, CXCL10, IL-1ra, IL-8, SPI,  
340 CXCL2, IL-6, MMP-1 and TNF $\alpha$  in one or more samples (Sup. Fig. 9E). CXCL10, even in uninfected  
341 samples, was significantly increased (p value reported) under both COMMD2 and p62 RNAi conditions,  
342 potentially suggesting a role of each in its regulation.

343 Overall, these results are the first evidence that COMMD2 is indeed a selective negative  
344 regulator of NF- $\kappa$ B dependent gene transcription. Moreover, analysis of the targeted genes suggests  
345 an unknown chromatin level component in the role of COMMD2 – p65 for gene expression.

346

#### 347 COMMD2 nuclear translocation favors invasive pneumococcal strains.

348 Since COMMD2 nuclear localization only occurred during TIGR4 challenge we sought to  
349 substantiate whether key TIGR4 virulence determinants were responsible. We first investigated  
350 whether Pneumolysin (Ply) or hydrogen peroxide production via Pyruvate oxidase (SpxB) were  
351 responsible for COMMD2 nuclear translocation.

352 Herein, we challenged GFP-COMMD2 cells with the  $\Delta$ Ply or  $\Delta$ SpxB TIGR4 mutants alongside  
353 their parental wildtype strain (Fig. 8A). Comparing  $\Delta$ SpxB to  $\Delta$ Ply and their parental wildtype showed  
354 that a  $\Delta$ Ply mutant does not trigger translocation, whereas the  $\Delta$ SpxB mutant induced a partial  
355 phenotype with  $\Delta$ SpxB increasing nuclear COMMD2 levels over  $\Delta$ Ply but remaining at 75-80% of  
356 wildtype (Fig. 8B). Given this result, we tested if a functional pneumolysin pore was required. For this  
357 we used the JWTIGR4  $\Delta$ Ply W433F pore mutant<sup>49,50</sup>. This mutant did not induce COMMD2  
358 translocation (Fig. 8B). Altogether we concluded that COMMD2 translocation was dependent on  
359 Pneumolysin pore formation in combination with SpxB.

360 However, the  $\Delta$ SpxB phenotype was puzzling as the strain retains functional native PLY yet  
361 still has reduced COMMD2 levels in comparison to wildtype TIGR4. This disparity suggested that both  
362 SpxB and PLY are necessary for COMMD2 nuclear accumulation under wild type conditions. We  
363 addressed the synergy between PLY and SpxB by comparing different phenotypes using exogenous  
364 purified Pneumolysin toxin alone or in combination with the main byproduct of SpxB, hydrogen  
365 peroxide. We first determined the IC<sub>50</sub> for hydrogen peroxide and purified Pneumolysin toxin  
366 individually at 28.30 $\mu$ M and 7.10nM, respectively, however when combined the calculated IC<sub>50</sub> for  
367 hydrogen peroxide dropped to 10 $\mu$ M (Sup. Fig. 10A & B). These results show that the combination of  
368 PLY and SpxB impact cellular toxicity more than with each individual component<sup>51</sup>.

369 We then tested the impact of exogenous supplementation of 0 – 6.25 $\mu$ M hydrogen peroxide  
370 during challenge with either a wildtype, a TIGR4  $\Delta$ SpxB, or a TIGR4  $\Delta$ SpxB $\Delta$ Ply mutant strain (Sup. Fig.  
371 10D – F). Our results showed increasing concentration of exogenous hydrogen peroxide resulted in  
372 TIGR4 $\Delta$ SpxB phenocopying wildtype except at the highest concentrations, where wildtype induced  
373 more nuclear COMMD2. There was no significant increase in nuclear COMMD2 levels for either the  
374 TIGR4  $\Delta$ SpxB $\Delta$ Ply or JW TIGR4 $\Delta$ PLY W433F pore mutants against their parental wildtype strains (Sup.  
375 Fig. 10E & F). Overall, these data suggest, at least for TIGR4, that PLY and hydrogen peroxide are  
376 mutually synergistic in driving nuclear COMMD2 levels.

377 Capsule is another key bacterial determinant of pneumococcus and drives many virulence  
378 mechanisms. We therefore tested whether capsule was required for COMMD2 nuclear translocation.

379 By comparing a wild type (JW TIGR4) to a capsule mutant (JW TIGR4 $\Delta$ CPS), we observed no difference  
380 in their ability to induce nuclear translocation of COMMD2 (Fig. 8E).

381 We next assessed the association of COMMD2 nuclear localization with isolates favoring  
382 either commensal-like/carriage (6B ST138, 11A ST6521 & 19A ST276) or invasive (1 ST304 or 1 ST306  
383 - which harbors a non-hemolytic Pneumolysin toxin) for their capacity to drive COMMD2 nuclear  
384 translocation. As expected, our results showed that invasive TIGR4 challenge significantly increased  
385 nuclear COMMD2 ( $pV \leq 0.0001$ ) in comparison to the commensal-like 6B ST90 isolate and uninfected  
386 cells (Fig. 8E). Comparing the invasive serotype 1 ST304 and ST306 (non-hemolytic) isolates to TIGR4  
387 revealed no significant differences in their capacity to induce nuclear COMMD2, whereas the  
388 commensal-like/carriage 11A ST6521 and 19A ST276 isolates resembled 6B ST90 which did not display  
389 COMMD2 localization (Fig. 8E). Interestingly, the two 6B strains, which only differ in their genomic  
390 sequence rather than their capsule, were phenotypically different in their nuclear COMMD2 levels. In  
391 contrast to 6B ST90 (Global Pneumococcal Sequence Cluster<sup>52</sup>; GPSC 23), 6B ST138 (GPSC 24) not only  
392 induced significantly ( $pV \leq 0.05$ ) more COMMD2 translocation in comparison with the uninfected  
393 control but had an elevated level compared to 6B ST90 ( $pV = 0.07$ ; Fig. 8E). Given this result, we  
394 assessed whether the elevated COMMD2 levels with 6B ST138 correlated with in vivo lethality using  
395 two challenge doses in an intranasal murine challenge model comparing 6B ST138 to TIGR4 (Fig. 8F &  
396 Sup. Fig 10G). At the high dose 6B ST138 induced lethality to a comparable level to that of TIGR4,  
397 which stands in contrast to our previously demonstrated findings that 6B ST90 was not lethal in this  
398 model even at a log higher dose to that of TIGR4<sup>6</sup>. Therefore, we concluded that in a dose dependent  
399 manner challenge with 6B ST138 (GPSC 24) has higher pathogenic potential than 6B ST90 (GPSC 23),  
400 and this correlates with the differential COMMD2 nuclear signal. Overall, the combination of these  
401 data provides strong evidence that COMMD2 translocation is predominantly associated with  
402 pneumococcal virulence phenotypes both in vitro and in vivo.

403

#### 404 **Discussion:**

405 Cellular inflammatory response is a critical component of the host defense to bacteria. Yet,  
406 the molecular processes that fine-tune cellular immunity cascades across the range of colonizing to  
407 virulent bacteria are poorly understood. We show that an invasive *S. pneumoniae* TIGR4 strain, which  
408 causes symptomatic disease in murine models<sup>6</sup>, drives a different NF- $\kappa$ B p65 activation profile in  
409 comparison to a commensal-like 6B ST90 strain and IL-1 $\beta$  – a potent inflammatory cytokine. Our mass  
410 spectrometry interactome and post-translational modification analysis, showed these two  
411 pneumococcal isolates have diverging p65 interacting partners and phosphorylation status. Analysis  
412 of these partners demonstrated that the invasive TIGR4 strain enriched for aggrephagy pathway  
413 components and COMMD2, whereas the 6B ST90 strain did not. Through our study of COMMD2 we  
414 show that TIGR4 triggers p65 degradation and induces a unique interaction of COMMD2 with p65 and  
415 p62. By deeply investigating this process we discovered COMMD2 is a negative regulator of cellular  
416 immunity and its nuclear levels associated with invasive favoring pneumococcal isolates. Altogether,  
417 we show a bacterial pathogenesis mechanism repressing host cellular immunity through bacterial  
418 driven degradation of NF- $\kappa$ B p65 via novel fine-tuning of its interacting partners.

419 Negative regulation of NF- $\kappa$ B signaling, in contrast to the breadth of knowledge on activatory  
420 mechanisms, is poorly documented. This is in part due to the lack of identified targets and mechanisms  
421 responsible for attenuating this signaling cascade. Of the known negative regulators, A20 (TNIP3)  
422 and COMMD1 are the better described with the studies using cytokine stimulation. Pointedly neither  
423 of these proteins were found in our TIGR4 p65 interactome, which suggests that COMMD2  
424 recruitment during bacterial infection is specific. A20 is primarily a deubiquitinase whose transcription  
425 is NF- $\kappa$ B activation dependent. A20 functions in a negative feedback loop to deubiquitinate NEMO,  
426 which results in its stabilization with the IKK complex to restore NF- $\kappa$ B sequestration in the cytoplasm.  
427 This ultimately terminates the downstream canonical NF- $\kappa$ B signaling cascade of inflammatory  
428 response<sup>18,25,53</sup>. In contrast, COMMD1 transcription is NF- $\kappa$ B independent, and facilitates p65  
429 termination by CRM1 mediated export and translocation of p65 to the proteasome for degradation,

430 while in parallel occupying the formerly p65 bound kappa-binding site at specific gene promoters  
431 <sup>27,29,30,32,34,35 33</sup>. It was put forth that the diversity of potential COMMD and NF- $\kappa$ B assemblies respond  
432 to an array of physiological stimuli to fine-tune cellular immunity positioning this family of proteins as  
433 powerful selective negative regulators of NF- $\kappa$ B signaling. Interestingly, our post-translational  
434 modification analysis of COMMD2 discovered a ubiquitinated peptide associated with a lysine at  
435 residue 50, which aligns with our results indicating selective degradation of COMMD2-p65-p62  
436 complex. The COMMD2 negative feedback loop on p65 that we uncover here may represent, even in  
437 a cellular state without bacterial infection, a precise mechanism to terminate or shift a given p65  
438 dependent transcription repertoire.

439 Given the vast array of post-translational modifications on p65 and other NF- $\kappa$ B subunits  
440 across differential stimulations has given rise to the “NF- $\kappa$ B barcode hypothesis”, which suggests that  
441 distinct patterns are linked to how inflammatory gene transcription occurs <sup>54,55</sup>. Supporting this is our  
442 exploratory mass spectrometry of p65 phosphorylation, which identified serine 45 (S45) as the only  
443 enriched phosphorylated mark during TIGR4 challenge. This mark has previously been shown to  
444 negatively regulate p65, although the mechanism is unknown <sup>56</sup>. Lanucara et al., showed that a  
445 phosphomimetic mutant of S45 prevented IL-6 transcription and p65 binding to the IL-6 promoter  
446 after 3 hours of TNF $\alpha$  stimulation <sup>56</sup>. It remains to be evaluated how this modification affects  
447 COMMD2-p62 degradation of p65 or upon repressing p65 host transcription. Notably our previous  
448 studies showed TIGR4 challenge induces de-phosphorylation of histone H3 serine 10, which is an  
449 essential histone modification associated with inflammatory gene transcription <sup>41,57</sup>. Understanding  
450 how this event relates to p65 turnover and COMMD2 may shed light on essential chromatin  
451 remodeling dynamics needed to precisely regulate NF- $\kappa$ B p65 DNA binding, extraction and  
452 transcription termination not only to pneumococci but also under inflammatory stimuli. Excitingly,  
453 the commensal-like 6B ST90 does not induce phosphorylation of this S45 residue. Instead, this strain  
454 leads to phosphorylation on S203 in addition to S536 and S276. These marks may be critical for the  
455 upregulation of the histone demethylase KDM6B, which we previously showed was required for  
456 bacterial containment in the upper respiratory tract <sup>6</sup>. Future investigations here may be the best  
457 positioned to decipher outstanding questions on how bacteria engage the non-canonical NF- $\kappa$ B  
458 pathway and how KDM6B is selectively recruited to gene targets during bacterial infection. Whether  
459 differential phosphorylation of p65 is the determining factor in the host response to different strains  
460 of pneumococcus remains to be determined. It is tempting to speculate that posttranslational  
461 modifications of p65 may represent markers of either host response to commensal or to invasive  
462 bacteria.

463 To date our work is the first to show that COMMD2 mediates p65 turnover through p62 and  
464 aggrephagy, a selective form of autophagy, while simultaneously repressing host cellular immunity.  
465 TIGR4, along with other pneumococcal isolates associated with higher virulence potential, triggered  
466 COMMD2 nuclear accumulation. These findings suggest that nuclear localization of COMMD2 could  
467 be a marker of virulence, distinguishing the host response from commensal-like isolates. We show  
468 that COMMD2 nuclear translocation was independent of the TIGR4 capsule, but dependent on a  
469 tandem function of Pneumolysin (Ply) and Pyruvate oxidase (SpxB), as a  $\Delta$ Ply mutant shows no  
470 COMMD2 nuclear accumulation, but a  $\Delta$ SpxB mutant induced partial COMMD2 translocation with a  
471 distinct phenotype. Our efforts titrating hydrogen peroxide, the product of *SpxB*, with the TIGR4  
472  $\Delta$ SpxB $\Delta$ Ply or JW TIGR4 $\Delta$ PLY W433F pore mutants revealed at least for TIGR4, PLY and hydrogen  
473 peroxide are mutually synergistic in driving nuclear COMMD2 levels and strongly support that  
474 Pneumolysin may be “masking” other bacterial effectors. Given the documented influence of  
475 Pneumolysin toxin, like other CDC toxins, on host plasma membrane, the known differences in  
476 Pneumolysin alleles <sup>58</sup>, and the known role of COMMD proteins, along with CCDC22 and CCDC93 (the  
477 CCC complex), in phosphatidylinositol-3-phosphate (PI3P) equilibrium within endosomes <sup>44</sup> raises the  
478 possibility that combinations of Pneumolysin toxin alleles with hydrogen peroxide may alter host  
479 membrane compositions. Deeper comparative studies between pneumococcal isolates and virulence  
480 associated bacterial protein mutants may likely identify new bacterial proteins that alter host

481 response. Moreover, our comparison of two serotype 6B isolates varying in sequence type and Global  
482 Pneumococcal Sequence Cluster resulted in different COMMD2 nuclear amounts which correlated  
483 with increased 6B ST138 (GPSC 24) dose dependent lethality during intranasal murine challenge. Thus,  
484 we propose invasive favoring pneumococcal isolates, as opposed to commensal-like ones, shape host  
485 cellular immunity, and potentially disease onset and lethality, through potent shifts in host  
486 transcription factor partners.

487 Tuning cellular immunity is fundamental for processes of airway epithelial cells exposed to  
488 pneumococcus<sup>7,59</sup>. The pro-inflammatory cytokines, TNF- $\alpha$  and IL-1 $\beta$ , are major cytokines necessary  
489 for neutrophil recruitment and are found in bronchoalveolar lavage fluid of animals challenged with  
490 pneumococcal isolates<sup>7,59,60</sup>. However, a study showed that isolated murine lung epithelial cells  
491 exposed to serotypes 19 and 3 failed to induce p65 (RelA) nuclear translocation in comparison to TNF $\alpha$   
492 and IL-1 $\beta$  cytokine treatment alone<sup>7</sup>. Indeed during respiratory infection with other microbes<sup>61,62</sup>, a  
493 balance is needed between pro-inflammatory responses and negative regulation to ensure minimal  
494 tissue damage from the influx of neutrophils into the airway tissues<sup>60</sup>. Airway epithelial cells play a  
495 crucial role in both situations by regulating neutrophil recruitment and promoting epithelial repair  
496 pathways leading to tissue resilience and resolution of inflammation<sup>59,60,63,64</sup>. With invasive  
497 pneumococci actively antagonizing the ability of airway epithelial cells to mount a cellular immune  
498 response, we hypothesize an amplifying and runaway inflammatory cascade is created in latter stages  
499 of infection where neutrophil influx is detrimental<sup>59,64,65</sup>. This could lead to exacerbated and severe  
500 pneumonia with excessive tissue damage, allowing pneumococcus to transmigrate to deeper tissues.  
501 We put forth that COMMD2, or combinations of COMMD proteins are modulators of bacterial driven  
502 inflammatory processes and may represent a therapeutic target to circumvent collateral tissue  
503 damage.

504 In conclusion, our study shows a new regulatory role for COMMD2 in restraining p65 through  
505 aggrephagy mediated turnover triggered by bacterial interaction. We reveal this process to be specific  
506 to invasive TIGR4 pneumococcal challenge and partially depend on pneumolysin. Further studies  
507 characterizing both the p65 and COMMD2 interactome under bacterial challenge with isolates  
508 representing divergent pneumococcal host interaction may identify new processes exploited at the  
509 microbe-host interface to regulate cellular immunity.

## 510 **Materials and methods:**

511 **Bacteria strains, growth, and enumeration.** Pneumococcal isolates of 6B ST90 CC156 lineage F (ST90),  
512 6B ST138, 11A ST6521, 19A ST276, 1 ST304 or 1 ST306, and TIGR4 were obtained from either the  
513 Centre National de Référence des Pneumocoques (Emmanuelle Varon; Paris, France) or (Thomas  
514 Kohler, Universität Greifswald) respectively. JW TIGR4 and  $\Delta$ W433F pore mutants were a gift from Dr.  
515 Jeffrey N. Weiser<sup>49</sup>. The TIGR4  $\Delta$ SpxB and TIGR4  $\Delta$ SpxB $\Delta$ Ply mutants were generated previously<sup>41</sup>.  
516 Experimental starters were made from master glycerol stocks struck on 5% Columbia blood agar plates  
517 (Biomerieux Ref# 43041) and grown overnight at 37°C with 5% CO<sub>2</sub> prior to outgrowth in Todd-Hewitt  
518 (BD) or Brain heart infusion (BHI) broth as previously described<sup>6</sup>. Inocula were prepared from frozen  
519 experimental stocks grown for 3 – 4 hrs to midlog phase in BHI at 37°C with 5% CO<sub>2</sub> in closed falcon  
520 tubes. Bacterial cultures were pelleted at 1,500xg for 10 mins at room temperature (RT), washed in  
521 DPBS, and concentrated in 1mL DPBS prior to dilution at desired CFU/mL using 0.6 OD<sub>600</sub> /mL  
522 conversion factors in desired cell culture media<sup>6</sup>. Bacterial counts were determined by serial dilution  
523 plating on 5% Columbia blood agar plates and grown overnight at 37°C with 5% CO<sub>2</sub>.

524  
525  
526 **Cell culture conditions and in vitro challenge.** A549 human epithelial cells (ATCC ref# CCL-185) and  
527 A549 stable cell lines were maintained in F12K media (Gibco) supplemented with 1x GlutaMax (Gibco)  
528 and 10% heat inactivated fetal calf serum (FCS) at 37°C with 5% CO<sub>2</sub>. Primary human nasal epithelial  
529 cells (HNEpC; PromoCell ref# C-12620; lot# 475Z023) were cultured and maintained in PneumaCult™-  
530 Ex Plus Medium (STEMCELL Technologies cat# 16237380). All cell lines were discarded after passage  
531 4. For challenge studies cells were plated in tissue culture treated plates at 2x10<sup>5</sup> cells (6well; for 72

532 hrs),  $5 \times 10^4$  cells (24well; for 48 hrs), or  $1 \times 10^4$  cells (96well; for 48 hrs)<sup>66</sup>. Bacterial inocula (Multiplicity  
533 of infection (MOI) 20) were diluted in cell culture media, added to cells, and bacterial-epithelial cell  
534 contact synchronized by centrifugation at 200xg for 10 mins at RT. Plates were moved to 37°C with  
535 5% CO<sub>2</sub> for 2 hrs and processed as desired for experiment termination. For inhibitor studies, cell  
536 culture media was aspirated, and replaced with filter sterilized culture media containing either  
537 Bafilomycin A1 400 nM final concentration (Sigma ref# SML1661) or Leptomycin B 10 nM final  
538 concentration (Sigma ref# L2913) for 3 hrs prior to bacterial addition. Human IL-1 $\beta$  (Enzo Life Sciences  
539 ref# ALX-522-056) was used at 10 ng/mL final concentration in cell culture media.

540

541 RNA isolation and RT-qPCR. Total RNA isolated and extracted using TRIzol (Life technologies  
542 ref#15596-026) method as per manufacturer's recommendations. Recovered RNA (5  $\mu$ g) was  
543 converted to cDNA with Super Script IV as per manufacturer's instructions, diluted to 20 ng/ $\mu$ L in  
544 molecular grade water and 1  $\mu$ L used for Sybr Green reactions as per manufacturer's instructions on  
545 a BioRad CFX384 (BioRad). Relative expression was calculated by  $\Delta\Delta$ Ct method to *GapDH*<sup>67</sup> with RT-  
546 PCR primers in Sup. Table 3<sup>6</sup>.

547

548 ChIP and ChIP-qPCR. Detailed ChIP buffer components and procedure were completed as previously  
549 reported<sup>66</sup>. Briefly,  $8 \times 10^6$  A549 cells were cross-linked with 1% formaldehyde at room temperature  
550 and quenched with 130 mM glycine. Chromatin was generated from the collected cell pellets by lysis  
551 and sonication in chromatin shearing buffer to a size of 200-900bp. ChIP grade antibody to p65 (L8F6)  
552 (CST ref #6956) was used at manufacturer's recommended concentrations and bound to DiaMag  
553 beads (diagenode ref # C03010021-150) overnight with gentle rotation. Quantified chromatin was  
554 diluted to 10  $\mu$ g per immunoprecipitation and added to antibody bound DiaMag beads overnight with  
555 gentle rotation and 8% of input reserved. Beads were washed as previously described<sup>66</sup>, and DNA  
556 purified using phenol-chloroform extraction followed by isopropanol precipitation. Recovered DNA  
557 suspended in molecular grade water was used for Sybr Green reactions (1  $\mu$ L) on a BioRad CFX384  
558 (BioRad). ChIP-qPCR primers (50-150 bp; 60 °C max melt temperature) were designed to span the NF-  
559  $\kappa$ B sites of interest within the promoters of *CFS2* or *PTGS2*<sup>68</sup>. % recovery was calculated as 2 raised  
560 to the adjusted input Ct minus IP Ct multiplied by 100. ChIP qPCR primers listed in Sup. Table 3.

561

562 Plasmids, molecular cloning and stable cell line generation. All plasmids and primers are listed in Sup.  
563 Table 3 . Routine cloning was carried out by in vivo assembly<sup>69,70</sup>. Briefly, primers were designed with  
564 a 15-20 bp overlap to amplify nucleic acid targets using Phusion Plus polymerase (Thermo ref# F630S).  
565 Correct sized bands were excised and nucleic acid extracted by "Freeze and squeeze"<sup>71,72</sup>. Herein,  
566 0.7% - 1% agarose gel fragments were frozen for 5 mins on dry ice and centrifuged for 15 mins at  
567  $>21,000$  xg with the supernatant collected – the process was completed two additional times.  
568 Collected supernatant containing nucleic acid was then purified using phenol-chloroform extraction  
569 followed by isopropanol precipitation and suspension in molecular grade water. Collected nucleic acid  
570 was quantified spectrophotometrically using a NanoDrop and mixed at 3:2 (vector: insert) in 10  $\mu$ l and  
571 added to chemically competent E. coli MC1061 or DH5 $\alpha$  for transformation. After 1 hr incubation on  
572 ice bacteria outgrowth was done for 1 hr in Luria-Bertani (BD) prior to selection on LB agar containing  
573 Ampicillin antibiotic (100  $\mu$ g/mL). All plasmids were isolated with the QIAprep Spin Miniprep Kit  
574 (Qiagen ref# 27106) and eluted in molecular grade water (endotoxin free) as per manufacturer's  
575 instructions. A549 stable cell lines were generated using the transposon-based sleeping beauty system  
576<sup>73,74</sup>. A549 cells were plated in tissue culture treated plates at  $2 \times 10^5$  cells (6well) one day prior to  
577 transfection with 2  $\mu$ g plasmid DNA + 150 ng SB100 transposase DNA. After transfection, cells were  
578 selected with 1 mg/mL Geneticin (Thermo ref# 10131035) for 7 days, with media exchanged on days  
579 1, 3, 5 & 7. Cells were collected with Trypsin 0.25% EDTA (Thermo ref# 25200056) and two-way serial  
580 diluted in a 96 well tissue culture plate for another 7 – 14 days with 1 mg/mL Geneticin to select  
581 colonies that were phenotypically bright were mixed and expanded prior to FACS sorting to ensure  
582 purity, and uniform expression.

583 Immunoblots and quantification. Whole cell lysates were obtained by RIPA lysis (10 mM Tris HCL pH  
584 7.5, 150 mM EDTA, 0.1% SDS, 1% Triton X-100 & 1% Deoxycholate) supplemented with inhibitor  
585 cocktail (1X PhosSTOP, 10 mM sodium butyrate, 0.2 mM PMSF). Samples combined with 5x with  
586 Laemmli buffer<sup>75</sup>, sonicated for 5 mins in a ultrasonic water bath, boiled at 98°C (dry bath) for 10 mins  
587 and frozen at -20°C. Whole cell lysates were ran on 4 – 20% pre-cast polyacrylamide SDS PAGE gels  
588 (BioRad), transferred to PVDF membrane (BioRad TransBlot) and blocked 1 hr in 5% BSA TBST at room  
589 temperature. Membranes were probed overnight at 4°C in 5% BSA TBST with primary antibody to p65  
590 (CST ref #6956 or CST ref# 8242), p65 phosphorylation at serine 536 (CST ref# 3033), p65  
591 phosphorylation at serine 276 (abcam ref# ab183559), SQSTM1 / p62 antibody [EPR4844] (abcam ref#  
592 ab109012) or actin AC-15 monoclonal (Sigma ref# A5441) as per manufacturer's recommendations.  
593 COMMD2 immunoblots were blocked for 1 hr at room temperature in 3% milk TBST and probed  
594 overnight at 4°C with the primary antibody (Sigma ref# HPA044190) suspended in 3% milk TBST.  
595 Appropriate secondary-HRP conjugated antibodies in 5% Milk TBST were incubated for 1 hr at room  
596 temperature prior to development with clarity ECL (BioRad) developing reagents with a ChemiDoc  
597 Touch (BioRad). Band intensity was quantified by Image Lab (BioRad) with linear intensity values log<sub>10</sub>  
598 transformed and normalized to actin prior to any additional ratio metric comparisons.

599  
600 siRNA and transfection. Primary human nasal cells were seeded at 2x10<sup>4</sup> cells per well in a 96well plate  
601 the day before RNAi transfection. For RNAi 1 µl of 2 µM Silencer Select siRNA stock for either COMMD2  
602 (Ambion ID# s27490; or Ambion ID# s27488) or SQSTM1 (p62; Ambion ID# s16961) was diluted with  
603 9 µl Opti-MEM (Thermo cat# 31985062) and mixed with 10 µl of 0.003% (vol/vol) Lipofectamine  
604 RNAiMAX (Thermo cat# 13778030)/ Opti-MEM. For COMMD2 siRNA mix, a final 2 µM concentration  
605 of siRNA was respected. Complexes were formed during 15 min incubation at room temperature prior  
606 to 20 µl of mixture added to previously seeded cells. 96well plate was incubated for an additional 72  
607 hrs 37°C with 5% CO<sub>2</sub> prior to challenge studies.

608  
609 Cell fractionation. Fractionation was performed as previously described as previously described<sup>66</sup>.  
610 Fraction lysates were combined with 5x with Laemmli buffer<sup>75</sup>, sonicated for 5 mins in a ultrasonic  
611 water bath, boiled at 98°C (dry bath) for 10 mins and frozen at -20°C. Samples were ran on either 10%  
612 (for GFP-COMMD2) or 12% (for fraction quality controls) polyacrylamide SDS PAGE gels (BioRad),  
613 transferred to PVDF membrane (BioRad TransBlot), blocked 1 hr in 5% BSA TBST at room temperature.  
614 Primary antibody in 5% BSA TBST to GFP (abcam ref# ab290), GapDH (abcam ref# ab8245), or histone  
615 H4 (abcam ref# ab177840) was completed overnight at 4°C. After 3x 10 min washes in TBST  
616 appropriate secondary-HRP conjugated antibodies in 5% Milk TBST were incubated for 1 hr at room  
617 temperature and developed with a ChemiDoc Touch (BioRad) as described above.

618  
619 Immunofluorescence microscopy and Cellprofiler analysis. For microscopy cells were seeded either on  
620 acid washed and UV treated coverslips (24well) or directly in 96well plates as described above. Two  
621 hours post-challenge media was aspirated, cells washed in DPBS, and fixed with 2.5% PFA for 10 mins  
622 at RT. Fixed cells were blocked and permeabilized overnight in 5% BSA 0.5% Tween20 at 4°C. Primary  
623 antibody to p65 (CST ref #6956 or CST ref# 8242), or p62 (SQSTM1; abcam ref# ab109012) were diluted  
624 at 1:1,000 in 5% BSA 0.5% Tween20, for time course of p65 phosphorylation at serine 536 cells were  
625 stained with MA5-15160 (Thermo; 1:1000), and incubated overnight at 4°C. Cells were washed 3x 10  
626 mins at RT in PBS + 0.1% Tween20 prior to 1 hr incubation at 1:1,000 dilution of either Alexa Fluor 594  
627 or Alexa Fluor 647 secondary antibody. Nuclei were stained with 10 ng/mL final concentration of  
628 Hoechst 33342 or Draq5 for 15 mins. Coverslips were rinsed in PBS and molecular grade water prior  
629 to mounting with Fluoromount-G Mounting Medium (INTERCHIM). Confocal microscopy images were  
630 acquired on a Nikon TiE inverted microscope with an integrated Perfect Focus System (TI-ND6-PFS  
631 Perfect Focus Unit) and a Yokogawa Confocal Spinning disk Unit (CSU-W1). Nine images per well were  
632 acquired using a 20X air objective (NA 0.75) at a step-size of 0.9µm in z-plane. Deconvoluted

633 epifluorescent images were acquired on a Cytation 5 (BioTek) using a 20X air objective (NA 0.75) with  
634 a grid of 3 x 3 (9 images en total).

635

636 Images were processed for background using Fiji <sup>76</sup>, and segmented using Cell Profiler <sup>77-79</sup>. Briefly,  
637 image analysis consisted of sequential modules to ‘IdentifyPrimaryObjects’ based on channel signal  
638 for nuclei (Hoechst 33342 or Draq5 stain), p65 (Alexa594), or p62 (Alexa594). This was followed by  
639 ‘IdentifySecondaryObjects’ for the GFP-COMMD2 signal via propagation of identified nuclei. Objects  
640 were related to each other to maintain cohesion between identified nuclei, cell and cellular contents  
641 (p65 or p62). For puncta, the additional module, ‘EnhanceorSupressFeatures’ with ‘Speckles’, was  
642 used. This used a global threshold strategy with Otsu threshold method and a 2% minimum boundary  
643 to identify puncta contained within the segmented nuclei.

644

645 Immunoprecipitation. Cells were lysed in 250  $\mu$ L of RIPA lysis (10 mM Tris HCL pH 7.5, 150 mM EDTA,  
646 0.1% SDS, 1% Triton X-100 & 1% Deoxycholate) supplemented with a protease mixture inhibitor  
647 (Roche Complete, EDTA free). Lysates were either immunoprecipitated using GFP-trap agarose beads  
648 (ChromoTek ref# gta-10) or with DynaBeads Protein G (Thermo ref# 10004D). For GFP-p65 and GFP-  
649 COMMD2 the samples were immunoprecipitated as per manufacturer’s instructions with the elution  
650 was recovered in either 5x with Laemmli buffer <sup>75</sup> and boiled at 98°C (dry bath) for 10 mins, or left in  
651 Trypsin digest buffer (see LC-MS/MS Mass-spectrometry and analysis). All samples were frozen at -  
652 20°C. For endogenous samples the lysates were incubated on a rotating wheel at 4 °C for 20 min before  
653 adding 1 mL of dilution buffer (150 mM NaCl and 50 mM Tris-HCl pH 7.5 supplemented with Protease  
654 mixture inhibitor) to reduce the detergent final concentration below 0.1%. The lysates were then  
655 centrifuged at 10,000  $\times$  g for 10 min. For p65 IP the lysates were then incubated with 2  $\mu$ g of antibody  
656 CST ref #6956) at 4 °C overnight before adding 50  $\mu$ L of Dynabeads for 1 hr. The beads were then  
657 washed three times in 0.01%Tween20 PBS before adding 20  $\mu$ L of Laemmli buffer supplemented with  
658 2%  $\beta$ -mercaptoethanol and boiled for 5 min.

659

660 Exogenous Hydrogen peroxide and Pneumolysin toxin challenges. For viability studies titrations of  
661 hydrogen peroxide (9 M stock, Thermo ref# 411881000; 0  $\mu$ M – 240  $\mu$ M) and Pneumolysin toxin  
662 (50 $\mu$ M stock; gift Dr. T. Mitchell; final 0 nM – 50 nM), concentrations were serial diluted into cell  
663 culture media. After 2 hrs of incubation samples were PFA fixed and nuclei stained with Draq5 (Thermo  
664 ref# 62252) to determine viability. Bacterial challenge experimental starters of TIGR4  $\Delta$ SpxB, TIGR4  
665  $\Delta$ SpxB $\Delta$ Ply, JW TIGR4 and  $\Delta$ W433F were grown and diluted in cell culture media as in “Bacterial strains,  
666 growth and enumeration”. These inocula were combined with cell culture media containing indicated  
667 hydrogen peroxide concentrations (0  $\mu$ M – 6.25  $\mu$ M) and added to cells seeded in 96 well plates. After  
668 2 hrs cells were PFA fixed and COMMD2 nuclear levels determined as in “Immunofluorescence  
669 microscopy and Cellprofiler analysis”.

670

671 Cytokine quantification by Luminex. Supernatants we collected from primary nasal epithelial cells  
672 seeded in a 96well plate as previously described. For this 200  $\mu$ l of supernatant per well was collected  
673 2 hrs post-challenge with IL-1 $\beta$  or bacteria, centrifuged in a 96well U-bottom plate for 10 min at 1,500  
674  $\times$  g to pellet bacteria and cellular debris. 120  $\mu$ l of cleared supernatant was collected into a 96well flat  
675 bottom plate and frozen at -20°C until use. Secretion in the supernatant of 29 proteins (Human  
676 Magnetic Luminex Assays, R&D Systems) was measured following manufacturer’s instructions using  
677 Luminex xMAP technology. Briefly, samples and standards were incubated with capture beads for 2  
678 hours at RT. After washing, detection antibody mix was added and incubated for 1 hour at RT. After  
679 washing, streptavidin-PE was added and incubated for 30 minutes at RT. Samples were acquired on a  
680 Bioplex 200 (Biorad). Analysis was performed using the Bioplex Manager Software. Concentration of  
681 each analyte was calculated using a 5-PL regression curve.

682

683 LC-MS/MS Mass-spectrometry and analysis. For label-free quantitative proteomic analysis of GFP-p65  
684 and GFP-COMMD2 the respected A549 cell lines were plated in 6well tissue culture plates, and  
685 challenged with bacteria for 2hrs as described above. One plate ( $\sim 5 \times 10^7$  cells) per condition was  
686 harvested using RIPA lysis and immunoprecipitated with GFP-trap agarose beads (ChromoTek ref# gta-  
687 10) as per manufacturer's instructions. Three or four independent biological replicates were prepared  
688 and analyzed for each condition. Prior to on-bead Trypsin digestion, the samples were washed 3x in  
689 trypsin digest buffer (20 mM Tris.HCl pH 8.0, 2 mM  $\text{CaCl}_2$ ).

690  
691 For pull down of GFP-p65 on bead digestion was performed strictly as described by Chromotek. Briefly,  
692 beads were suspended in digestion buffer (Tris 50 mM pH 7.5, urea 2 M, 1 mM DTT and 5  $\mu\text{g} \cdot \mu\text{l}$  of  
693 trypsin (Promega)) for 3 min at 30°C. Supernatants were transfer to new vials and beads were washed  
694 twice using (Tris 50 mM pH 7.5, urea 2 M and iodoacetamide 5 mM). All washes were pulled and  
695 incubated at 32°C for overnight digestion in the dark. Peptides were purified using C18 stage tips  
696 protocol<sup>80</sup>.

697  
698 LC-MS/MS analysis of digested peptides was performed on an Orbitrap Q Exactive Plus mass  
699 spectrometer (Thermo Fisher Scientific, Bremen) coupled to an EASY-nLC 1200 (Thermo Fisher  
700 Scientific). A home-made column was used for peptide separation ( $\text{C}_{18}$  30 cm capillary column picotip  
701 silica emitter tip (75  $\mu\text{m}$  diameter filled with 1.9  $\mu\text{m}$  Reprosil-Pur Basic  $\text{C}_{18}$ -HD resin, (Dr. Maisch GmbH,  
702 Ammerbuch-Entringen, Germany)). It was equilibrated and peptide were loaded in solvent A (0.1 %  
703 FA) at 900 bars. Peptides were separated at 250  $\text{nl} \cdot \text{min}^{-1}$ . Peptides were eluted using a gradient of  
704 solvent B (80% ACN, 0.1 % FA) from 3% to 31% in 45 min, 31% to 60% in 17 min, 60% to 90% in 5 min  
705 (total length of the chromatographic run was 82 min including high ACN level step and column  
706 regeneration). Mass spectra were acquired in data-dependent acquisition mode with the XCalibur 2.2  
707 software (Thermo Fisher Scientific, Bremen) with automatic switching between MS and MS/MS scans  
708 using a top 12 method. MS spectra were acquired at a resolution of 70000 (at  $m/z$  400) with a target  
709 value of  $3 \times 10^6$  ions. The scan range was limited from 300 to 1700  $m/z$ . Peptide fragmentation was  
710 performed using higher-energy collision dissociation (HCD) with the energy set at 27 NCE. Intensity  
711 threshold for ions selection was set at  $1 \times 10^6$  ions with charge exclusion of  $z = 1$  and  $z > 7$ . The MS/MS  
712 spectra were acquired at a resolution of 17500 (at  $m/z$  400). Isolation window was set at 1.6 Th.  
713 Dynamic exclusion was employed within 30 s. Recorded spectra were searched with MaxQuant  
714 (version 1.5.3.8) using the Andromeda search engine<sup>81</sup> against a human database (74368 entries,  
715 downloaded from Uniprot the 27<sup>th</sup> of September 2019), a Streptococcus pneumoniae R6 database  
716 (2031 entries, downloaded from Uniprot the 1<sup>st</sup> of January 2020) and a Streptococcus pneumoniae  
717 serotype 4 database (2115 entries, downloaded from Uniprot 1<sup>st</sup> of January 2020).

718  
719 The following search parameters were applied: carbamidomethylation of cysteines was set as a fixed  
720 modification, oxidation of methionine and protein N-terminal acetylation were set as variable  
721 modifications. The mass tolerances in MS and MS/MS were set to 5 ppm and 20 ppm respectively.  
722 Maximum peptide charge was set to 7 and 5 amino acids were required as minimum peptide length.  
723 At least 2 peptides (including 1 unique peptides) were asked to report a protein identification. A false  
724 discovery rate of 1% was set up for both protein and peptide levels. iBAQ value was calculated. The  
725 match between runs features was allowed for biological replicate only.

726  
727 For pull down of GFP-COMMD2, washed beads were re-suspended in 150  $\mu\text{l}$  digestion buffer (20 mM  
728 Tris.HCl pH 8.0, 2 mM  $\text{CaCl}_2$ ) and incubated for 4 hours with 1  $\mu\text{g}$  trypsin (Promega) at 37°C and shaking  
729 at 1200 rpm. Beads were removed, another 1  $\mu\text{g}$  of trypsin was added and proteins were further  
730 digested overnight at 37°C, shaking at 750 rpm. Peptides were acidified with trifluoroacetic acid (TFA)  
731 to lower the pH below 3 and desalted on reversed phase (RP) C18 OMIX tips (Agilent). The tips were  
732 first washed 3 times with 100  $\mu\text{l}$  pre-wash buffer (0.1% TFA in water/acetonitrile (ACN, 20:80, v/v))  
733 and pre-equilibrated 5 times with 100  $\mu\text{l}$  of wash buffer (0.1% TFA in water) before the sample was

734 loaded on the tip. After peptide binding, the tip was washed 3 times with 100  $\mu$ l of wash buffer and  
735 peptides were eluted twice with 100  $\mu$ l elution buffer (0.1% TFA in water/ACN (40:60, v/v)). The  
736 combined elutions were transferred to HPLC inserts and dried in a vacuum concentrator. The peptides  
737 were re-dissolved in 20  $\mu$ l loading solvent A (0.1% TFA in water/ACN (98:2, v/v)) of which 2  $\mu$ l was  
738 injected for LC-MS/MS analysis on an Ultimate 3000 RSLCnano system in-line connected to a Q  
739 Exactive HF mass spectrometer (Thermo). Trapping was performed at 10  $\mu$ l/min for 4 min in loading  
740 solvent A on a 20 mm trapping column (made in-house, 100  $\mu$ m internal diameter (I.D.), 5  $\mu$ m beads,  
741 C18 Reprosil-HD, Dr. Maisch, Germany). The peptides were separated on an in-house produced  
742 column (75  $\mu$ m x 250 mm), equipped with a laser pulled electrospray tip using a P-2000 Laser Based  
743 Micropipette Puller (Sutter Instruments), packed in-house with ReproSil-Pur basic 1.9  $\mu$ m silica  
744 particles (Dr. Maisch). The column was kept at a constant temperature of 50°C. Peptides eluted using  
745 a non-linear gradient reaching 33% MS solvent B (0.1% FA in water/acetonitrile (2:8, v/v)) in 60 min,  
746 55% MS solvent B in 75 min and 70% MS solvent B after 90 min at a constant flow rate of 300 nl/min.  
747 This was followed by a 5-minutes wash at 70% MS solvent B and re-equilibration with MS solvent A  
748 (0.1% FA in water). The mass spectrometer was operated in data-dependent mode, automatically  
749 switching between MS and MS/MS acquisition for the 12 most abundant ion peaks per MS spectrum.  
750 Full-scan MS spectra (375-1500 m/z) were acquired at a resolution of 60,000 in the Orbitrap analyzer  
751 after accumulation to a target value of 3,000,000. The 12 most intense ions above a threshold value  
752 of 13,000 were isolated (isolation window of 1.5 m/z) for fragmentation at a normalized collision  
753 energy of 30% after filling the trap at a target value of 100,000 for maximum 80 ms. MS/MS spectra  
754 (145-2,000 m/z) were acquired at a resolution of 15,000 in the Orbitrap analyzer. The  
755 polydimethylcyclosiloxane background ion at 445.120028 Da was used for internal calibration (lock  
756 mass) and QCloud<sup>82</sup> has been used to control instrument longitudinal performance during the project.  
757 Recorded spectra were searched with MaxQuant (version 2.0.3.0) using the Andromeda search engine  
758 with default search settings including a false discovery rate set at 1% on PSM, peptide and protein  
759 level.

760  
761 Spectra were searched against the *Streptococcus pneumoniae* setotype 4 (TIGR4) (Taxid: 170187)  
762 protein sequences in the Uniprot database (database release version of 04\_2022, UP000000585),  
763 containing 2,109 sequences ([www.uniprot.org](http://www.uniprot.org)), the *Streptococcus pneumoniae* (Taxid: 1313) protein  
764 sequences in the Uniprot database (database release version of 04\_2022, UP000046310), containing  
765 2,115 sequences ([www.uniprot.org](http://www.uniprot.org)) and the human protein sequences in the Swiss-Prot database  
766 (database release version of 2022\_01, reference proteome: UP000005640), containing 20,588  
767 sequences ([www.uniprot.org](http://www.uniprot.org)). The mass tolerance for precursor and fragment ions was set to 4.5 and  
768 20 ppm, respectively, during the main search. Enzyme specificity was set as C-terminal to arginine and  
769 lysine, also allowing cleavage at proline bonds with a maximum of three missed cleavages. Variable  
770 modifications were set to oxidation of methionine residues, acetylation of protein N-termini and lysine  
771 residues, phosphorylation of serine, threonine and tyrosine and ubiquitination of lysine residues.  
772 Matching between runs was enabled with a matching time window of 0.7 minute and an alignment  
773 time window of 20 minutes. Only proteins with at least one unique or razor peptide were retained  
774 leading to the identification of 2,328 proteins. Proteins were quantified by the MaxLFQ algorithm  
775 integrated in the MaxQuant software. A minimum ratio count of two unique or razor peptides was  
776 required for quantification.

777  
778 Data analysis for quantitative proteomics. Quantitative analysis was based on pairwise comparison of  
779 protein intensities. Values were log-transformed (log<sub>2</sub>). Reverse hits and potential contaminant were  
780 removed from the analysis. Proteins with at least 2 peptides were kept for further statistics after  
781 removing shared proteins from the uninfected GFP alone control. Intensity values were normalized by  
782 median centering within conditions (normalized function of the R package DAPAR<sup>83</sup>). Remaining  
783 proteins without any iBAQ value in one of both conditions have been considered as proteins  
784 quantitatively present in a condition and absent in the other. They have therefore been set aside and

785 considered as differentially abundant proteins. Next, missing values were imputed using the impute.  
786 MLE function of the R package imp4p (<https://rdrr.io/cran/imp4p/man/imp4p-package.html>).  
787 Statistical testing was conducted using a limma t-test thanks to the R package limma<sup>84</sup>. An adaptive  
788 Benjamini-Hochberg procedure was applied on the resulting p-values thanks to the function adjust.p  
789 of R package cp4p<sup>85</sup> using the robust method described in<sup>(86)</sup> to estimate the proportion of true null  
790 hypotheses among the set of statistical tests. The proteins associated to an adjusted p-value inferior  
791 to a FDR level of 1% have been considered as significantly differentially abundant proteins.

792

793 **Statistical analysis.** All experiments, unless otherwise noted, were biologically repeated 3–5 times and  
794 the statistical test is reported in the figure legend. Data normality was tested by Shapiro-Wilk test, and  
795 appropriate parametric or non-parametric tests performed depending on result. P values calculated  
796 using GraphPad Prism software and the exact values are in source data. Microscopy data obtained  
797 from analysis of 3 – 5 image fields per biological replicate after being automatically acquired by the  
798 microscope software to ensure unbiased sampling with the total number of analyzed cells or nuclei  
799 noted in the figure legend.

800

#### 801 **Data Availability:**

802 All data in the present study is available upon request from the corresponding authors. The mass  
803 spectrometry proteomics data of GFP-p65 and GFP-COMMD2 have been deposited to the  
804 ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers  
805 PXD032970 (p65) and PXD043886 (COMMD2).

806

#### 807 **Code Availability:**

808 No custom code or software was used in the manuscript.

809

#### 810 **Acknowledgements:**

811 We would like to thank Emmanuelle Varon and Thomas Kohler for their generous gifts of *S. pneumoniae*  
812 strains. We are appreciative of Pierre-Henri Commere and the Institut Pasteur, Flow Cytometry  
813 Platform (Paris, France) for sorting of the COMMD2 stable cell line. Finally, we would like to thank  
814 Daniel Hamaoui for his help processing blots during COVID-19 related work personnel restrictions.  
815 Michael G. Connor is supported by a Springboard to Independence grant (AirwayStasis) from the  
816 French Government's Investissement d'Avenir program, the Laboratoire d'Excellence "Integrative  
817 Biology of Emerging Infectious Diseases" (ANR-10-LABX-62-IBEID). Melanie A. Hamon received  
818 support from the French government through the National Research Agency (ANR) as part of the  
819 France 2030 program referenced "ANR-23-CHBS-0001" (ChromaBac). Work in the laboratory  
820 Chromatin and infection unit (headed by Melanie A. Hamon) is supported by the Institut Pasteur, the  
821 Fondation pour la Recherche Médicale (FRM- EQU202003010152), the Fondation iXCore-iXLife and  
822 the Pasteur-Weizmann research fund. Sebastian Baumgarten is supported by the Institut Pasteur and  
823 the European Commission (ERC-STG "PlasmoEpiRNA"). The views expressed in this article are those of  
824 the authors and not necessarily those of the NIHR, or the Department of Health and Social Care. Jost  
825 Enninga and Lisa Sanchez, members of Dynamics of host-pathogen interactions unit (Institut Pasteur),  
826 are supported by the European Commission (ERC-CoG-Endosubvert), the ANR-HBPsensing, and are  
827 members of the IBEID and Milieu Interieur LabExes. Filipe Carvalho was supported by a postdoctoral  
828 grant through the "Investissement d'Avenir" as part of a French "Laboratoire d'Excellence" (LabEx)  
829 research program: Integrative Biology of Emerging Infectious Diseases (ANR-10-LBX-62 IBEID). This  
830 work was also supported by EPIC-XS, project number 823839, funded by the Horizon 2020 program of  
831 the European Union.

832

#### 833 **Author contributions:**

834 Conceived and designed all experiments: MGC and MAH. Performed and analyzed data for all  
835 experiments: MGC with specific contributions from LS (confocal microscopy imaging); FC, MGE, & TC

836 (p65 mass spectrometry data, repeats for GFP & endogenous immunoprecipitations validations,  
837 analysis...); FI, SD and SB (COMMD2 mass spectrometry data, and analysis...), and CC (western blot  
838 and cell culture). MGC and TMNC conducted murine challenge models. MGC and MAH edited and  
839 reviewed the manuscript. MC and MAH supervised the research and secured funding. All authors  
840 approved the final manuscript.

841

842 **Conflict of interest statement:**

843 The authors declare no conflict of interest.

844 **Figure 1: TIGR4 p65 interactome is divergent from 6B ST90 and enriches for aggrephagy.** Mass-  
845 spectrometry interactome (n=4 biological replicates per condition) of immunoprecipitated GFP-p65  
846 from a stable A549 GFP-p65 cell line (1x10<sup>7</sup> cells total) 2 hrs post challenge with either 6B ST90 or  
847 TIGR4 (MOI 20). A) Experimental scheme of mass-spectrometry study. B) Tabular summary of NF-κB  
848 protein partners for TIGR4 and 6B in comparison to the GFP control. C-E) Volcano plots of TIGR4 vs.  
849 GFP (C), 6B ST90 vs. GFP (D), and TIGR4 vs. 6B ST90 (E). Known NF-κB p65 partners in blue and general  
850 significant targets in yellow. Lines represent -log<sub>10</sub>(pV) and fold-change (log<sub>2</sub>) cutoffs with targets of  
851 interested denoted. F) STRING GO Ontology analysis of significant TIGR4 targets with term strength  
852 and FDR. Full data in Sup. Table 1.

853

854 **Figure 2: TIGR4 engages NF-κB differently than commensal-like 6B ST90.** Immunoblot of A549 human  
855 airway epithelial cells 2 hrs post-challenge with either IL-1β (10 ng/ml), TIGR4 (MOI 20) or 6B ST90  
856 (MOI 20) (± IL-1β; 10 ng/ml). Whole cell lysates probed for p65, phosphorylated p65 at Serine 276,  
857 phosphorylated p65 at Serine 536 or Actin. A) Representative image of immunoblot. Actin normalized  
858 ratiometric B) phosphorylated p65 at Serine 5366 to total p65, C) phosphorylated p65 at Serine 276  
859 to total p65, and D) total p65. Dot blot with mean (red line). One-way ANOVA with Dunnett's multiple  
860 comparison post-hoc test for B & C. One-way ANOVA with Tukey's multiple comparison post-hoc test  
861 for D. Intergroup comparison paired T-Test for B-D. \*\*P ≤ 0.01, \*\*\*P ≤ 0.001, \*\*\*\*P ≤ 0.0001. Full  
862 blots provided in Supplementary Information 1. E) Representative BioTek objective focused Zstack (10  
863 μm) immunofluorescence microscopy of paraformaldehyde fixed A549 cells 2 h post-challenge with  
864 either IL-1β (10 ng/ml) or TIGR4 (± IL-1β 10 ng/ml; MOI 20) stained for phosphorylated p65 S536  
865 (magenta) and actin (phalloidin; gray). Scale bar = 50μm. F) Quantification of scaled (x16bit) mean  
866 nuclear intensity of phosphorylated p65 S536. Dot blot of mean ± SEM with connected line over time  
867 (n = 3 biological replicates; counts in Sup. Table 4). Comparisons are Paired T-Test at each time  
868 indicated. \* = significant; pV reported in Sup. Table 4.

869

870 **Figure 3: Blocking aggrephagy increases total COMMD2, p62 and p65.** Immunofluorescence confocal  
871 microscopy of stable A549 GFP-COMMD2 cells pre-treated with Bafilomycin A1 (400nM) or DMSO for  
872 3 h prior to 2 h post-challenge with either IL-1β (10 ng/ml) or TIGR4 (± IL-1β 10 ng/ml; MOI 20).  
873 Representative images Sup. Fig. 4 & 5. Bar graph of mean ± STD (n = 3 biological replicates for p65 and  
874 p62; n = 6 biological replicates for COMMD2; counts in Sup. Table 4). A & B) Quantified levels of total  
875 or nuclear COMMD2. C & D) Quantified levels of total or nuclear p62. E & F) Quantified levels of total  
876 or nuclear p65. G & H) Quantified area (pixels) of total p65 puncta or p62 puncta (n = 3 biological  
877 replicates for p65 and p62). For G & H Tukey box and whisker plot with defined box boundaries being  
878 the upper and lower interquartile range (IQR), whiskers' (fences) being ± 1.5 times IQR and the median  
879 depicted by the middle solid line. Dots represent outliers. One-way ANOVA with Tukey's multiple  
880 comparison post-hoc test for A - H. \*\*P ≤ 0.01, \*\*\*P ≤ 0.001, \*\*\*\*P ≤ 0.0001.

881

882 **Figure 4: TIGR4 challenge induces formation of a COMMD2 – p65 – p62 complex.** GFP-Trap agarose  
883 immunoprecipitants were collected from a stable A549 GFP-COMMD2 cell line 2 hrs post-challenge  
884 with either IL-1β (10 ng/ml) or TIGR4 (MOI 20) or 6B ST90 (MOI 20) (± IL-1β; 10 ng/ml). A & B)  
885 Representative immunoblot from 3 biological replicates of GFP-COMMD2 immunoprecipitation  
886 lysates (input & IP) probed for p65, p62 or GFP for COMMD2. Full blots provided in Supplementary  
887 Information 1.

888

889 **Figure 5: COMMD2-p65-p62 is exported from nucleus through CRM1.** Representative  
890 immunofluorescence confocal microscopy of stable A549 GFP-COMMD2 pretreated for 3 hrs with  
891 Leptomycin B (10 nM) prior to 2 hr challenge with either IL-1β (10 ng/ml) or TIGR4 (MOI 20).

892 Paraformaldehyde fixed cells stained for A) p62 (magenta), or B) p65 (cyan) against GFP-COMMD2  
893 (gray). Scale bar = 100  $\mu\text{m}$  or 10  $\mu\text{m}$  for single nuclei inserts. C & D) Co-association of intensity peaks  
894 across a 20  $\mu\text{m}$  segment (white line) for p62 (magenta) or p65 (cyan) to COMMD2 (black). E-G)  
895 Quantified nuclear intensity of COMMD2 (E), p62 (F), p65 (G) from untreated uninfected, IL-1 $\beta$  or  
896 TIGR4 conditions to Leptomycin B treatment. Graphed as mean  $\pm$  STD with dots representing biological  
897 replicates. Intergroup comparisons paired T.Test. \*P  $\leq$  0.05, \*\*P  $\leq$  0.01, \*\*\*\*P  $\leq$  0.0001.

898

899 **Figure 6: TIGR4 driven COMMD2 interactome is unique in comparison to 6B ST90 or IL-1 $\beta$ .** Mass-  
900 spectrometry interactome (n=2 biological replicates per condition) of immunoprecipitated GFP-  
901 COMMD2 from a stable A549 GFP-COMMD2 cell line ( $1 \times 10^7$  cells total) 2 hrs post challenge with either  
902 TIGR4 (MOI 20), 6B ST90 (MOI 20) or IL-1 $\beta$  (10 ng/ml). A) Experimental scheme of mass-spectrometry  
903 study. B – D) Volcano plots of TIGR4 vs. GFP-COMMD2 (B), 6B ST90 vs. GFP-COMMD2 (C), and IL-1 $\beta$   
904 vs. GFP-COMMD2 (D). Identified interacting partners with known NF- $\kappa\text{B}$  p65 interaction in blue and  
905 significant targets in yellow. Lines represent  $-\log_{10}(\text{pV})$  and fold-change cutoffs with targets of  
906 interested denoted. E) Venn diagram describing the numbers of unique and shared significant proteins  
907 and their total % from the mass-spectrometry dataset. Table breakdown of identified partners that  
908 were significant, of the significant targets that are unique, and of the significant targets shared with  
909 the p65 interactome. F) Panther classification analysis of protein class of identified COMMD2  
910 interactors unique to TIGR4, shared between TIGR4 and 6B ST90, or unique to 6B ST90.

911

912 **Figure 7: COMMD2 RNAi selectively elevates host analytes associated with cellular immunity.** A)  
913 Secreted analytes (Luminex) at 4 hrs from RNAi COMMD2 primary nasal cells normalized to scrambled  
914 controls (n=3 biological replicates). Cells were challenged with either IL-1 $\beta$  (10 ng/ml) or TIGR4 (MOI  
915 20)  $\pm$  IL-1 $\beta$  (10 ng/ml). Individual p values shown in comparison to respected Scr control. Calculated  
916 by unpaired T. Test. B) Absolute difference of COMMD2 RNAi to scramble control for all analytes. Dot  
917 blot with mean (bars). Wilcoxon matched pairs signed rank test to TIGR4. ns = not significant, \*P  $\leq$   
918 0.05, \*\*\*\*P  $\leq$  0.0001. C) Difference of either RNAi COMMD2 or p62 against scramble control for TIGR4  
919 and 6B ST90. Before-after line graph. Wilcoxon matched-pairs signed rank test to TIGR4. \*P  $\leq$  0.05,  
920 \*\*P  $\leq$  0.01, \*\*\*P  $\leq$  0.001, \*\*\*\*P  $\leq$  0.0001. D) Transcription factor Affinity Prediction (TRAP) analysis<sup>47</sup>  
921 of predicted NF- $\kappa\text{B}$  binding motifs  $\pm$  2kb of indicated gene TSS. Scale bar represents predicted affinity  
922 score color coded. E) Weblogo<sup>48</sup> visual of nucleotide probability of COMMD2 target genes in comparison  
923 to canonical JASPAR NF- $\kappa\text{B}$  motif and all targets. Full details of analysis in Sup. Table 4.

924

925 **Figure 8: Invasive favoring pneumococcal isolates drive COMMD2 nuclear localization.** A)  
926 Immunofluorescence deconvolution epifluorescence microscopy of A549 GFP-COMMD2 (gray) cells 2  
927 hr post-challenge with either IL-1 $\beta$  (10 ng/ml), or MOI 20 for each bacterial strain 6B ST90, 6B ST138,  
928 11A ST6521, 19A ST276, 1 ST304, 1 ST306, JW TIGR4 (JW parental wildtype), JW TIGR4  $\Delta\text{cps}$ , JW TIGR4  
929  $\Delta\text{ply}$  W433F, TIGR4 (parental wildtype), TIGR4  $\Delta\text{spxB}$  or TIGR4  $\Delta\text{ply}$ . Relevant bacterial strain  
930 information for favoring carriage or invasive host states along with mutant genotypes. Scale bar =  
931 50 $\mu\text{m}$ . B-E) Bar graph of mean  $\pm$  STD quantification of nuclear GFP-COMMD2 normalized to the  
932 segmented nuclei using DAPI signal (omitted in representative images for clarity; B,D & E n = 3  
933 biological replicates; C n = 6 biological replicates; counts in Sup. Table 4). One-way ANOVA with Tukey's  
934 multiple comparison post-hoc test for A - H. \*\*P  $\leq$  0.01, \*\*\*P  $\leq$  0.001, \*\*\*\*P  $\leq$  0.0001. F) C57B6 mice  
935 (8-9weeks) were intranasally challenged with TIGR4 (3 -  $4 \times 10^6$  CFU; n=3), 6B ST138 (3 -  $4 \times 10^6$  CFU;  
936 n=6), or 6B ST138 (3 -  $4 \times 10^7$  CFU; n=6). Survival monitored for 14 days post-infection. Kaplan-Meier  
937 percent survival curve with Holm-Šidák's multiple comparisons test. \*\*P  $\leq$  0.01. # = single animal  
938 survived.

939 **Sup. Figure 1: Individual GO biological process enrichment for TIGR4 and 6B ST90 p65 interactomes.**

940 A-B) TIGR4 or 6B ST90 enrichment over GFP. Lollipop graph indicating FDR by color scale and number  
941 of proteins by lollipop size.

942

943 **Sup. Figure 2: TIGR4 drives disparity in NF- $\kappa$ B gene expression and chromatin binding.** A-B)

944 phosphorylated p65 at Serine 536 or Serine 276 to actin. C) Immunoblot of primary nasal whole cell  
945 lysates 2 hrs post-challenge with either IL-1 $\beta$  (10 ng/ml), TIGR4 (MOI 20) or 6B ST90 (MOI 20) ( $\pm$  IL-1 $\beta$ ;  
946 10 ng/ml) probed for phosphorylated p65 at Serine 536 and actin (n=3 biological). A – C) Dot blot with  
947 mean (red line). One-way ANOVA with Dunnett's multiple comparison post-hoc test. Intergroup  
948 comparison paired T-Test. \*\*P  $\leq$  0.01, \*\*\*P  $\leq$  0.001, \*\*\*\*P  $\leq$  0.0001. Full blots provided in  
949 Supplementary Information 1. D-E) Inflammatory gene transcription profiles by RT-qPCR for PTGS2 &  
950 CSF2 of A549 cells over a 2 hr time course with either IL-1 $\beta$  or TIGR4 ( $\pm$  IL-1 $\beta$  10 ng/ml; MOI 20).  
951 Graphed as the relative expression of each indicated transcript to matched uninfected/unstimulated  
952 control per time point (n = 3 biological replicates; 2 technicals per replicate). Displayed as a dot plot  
953 with each data point and a bar representing the mean. Statistics table reporting significance calculated  
954 by unpaired T-Test at each time point indicated. \* = significant; full details of analysis in Sup. Table 4.  
955 F) Schematic representation of PTGS2 or CSF2 promoter with ChIP-qPCR primer locations and NF- $\kappa$ B  
956 sites denoted as predicted by Alibaba2-curated eukaryotic transcription factor DNA-binding motifs  
957 from the TRANSFAC database<sup>68</sup>. G-H) 10 $\mu$ g chromatin input from A549 cells either untreated (light  
958 gray), IL-1 $\beta$  treated (10 ng/ml; dark gray) or 2 hrs post-challenge with TIGR4 ( $\pm$  IL-1 $\beta$ ; 10 ng/ml; MOI  
959 20; light blue or dark blue respectively). ChIP-qPCR represented as % recovery against input of p65 at  
960 indicated NF- $\kappa$ B sites. Tukey box and whisker plot with defined box boundaries being the upper and  
961 lower interquartile range (IQR), 'whiskers' (fences) being  $\pm$  1.5 times IQR and the median depicted by  
962 the middle solid line (n=3 biological replicates with 2 or 3 technicals per replicate). One-way ANOVA  
963 comparing all means with Tukey's multiple comparison post-hoc test. ns=not significant, \*\*\*\*P  $\leq$   
964 0.0001.

965

966 **Sup. Figure 3: Proteasomal degradation is not involved in TIGR4 mediated p65 turnover.** Cell

967 fractions from a stable A549 GFP-COMMD2 cell line 2 hrs post-challenge with either IL-1 $\beta$  (10 ng/ml),  
968 TIGR4 (MOI 20) or 6B ST90 (MOI 20). A) Representative immunoblot of cell fractions probed for GFP  
969 (COMMD2) enrichment across cellular compartments with GapDH (cytoplasm control) or H4 (nuclear  
970 control). B) Quantified nuclear COMMD2 (n = 3 biological). Bar graph with dots representing  
971 experiments. One-way ANOVA with Tukey's multiple comparison post-hoc test. ns = not significant,  
972 \*\*\*\*P  $\leq$  0.0001. C) Representative immunoblot of cell fractions and coomassie stained PVDF  
973 membrane.

974

975 **Sup. Figure 4: Representative images of COMMD2 & p65 with Bafilomycin A1.** Representative  
976 confocal microscopy images. Puncta analysis of area in pixels highlighted with color scale.

977

978 **Sup. Figure 5: Representative images of COMMD2 & p62 with Bafilomycin A1.** Representative  
979 confocal microscopy images. Puncta analysis of area in pixels highlighted with color scale.

980

981 **Sup. Figure 6: TIGR4 induces endogenous COMMD2-p65 complex.** A) Representative immunoblot of

982 p65 immunoprecipitation from primary nasal cells 2 hr post-challenge with either TIGR4 or 6B ST90  
983 (MOI 20; n= 4 biological). B-D) Quantified ratio of p65 to COMMD2 (prey :: bait) normalized to  
984 uninfected (B), target COMMD2 ratio to uninfected normalized to input (C) and bait p65 ratio to  
985 uninfected normalized to input (D). Dot and bar graph. (B) Kruskal-Wallis test with Dunn's multiple

986 comparison test. C-D) One-way ANOVA with Bonferroni's multiple comparison post-hoc test. \*P ≤  
987 0.05.

988

989 **Sup. Figure 7: CRM1 inhibition increases p62 puncta.** A) Representative immunofluorescence  
990 confocal microscopy of stable A549 GFP-COMMD2 pretreated for 3 hrs with Leptomycin B (10 nM)  
991 prior to 2 hr challenge with either IL-1β (10 ng/ml) or TIGR4 ± IL-1β (MOI 20). Paraformaldehyde fixed  
992 cells stained for p62 (magenta) against GFP-COMMD2 (gray) and nuclei (DAPI; n=3 biological  
993 replicates; nuclei counts for Uninfected n=1041, IL-1β n=831, TIGR4 n=1164, TIGR4 + IL-1β n=1269).  
994 Scale bar = 10 μm. B) Nuclear p62 puncta average counts per cell. Graphed as mean with dots  
995 representing individual experiments. One-way ANOVA comparing all means with Tukey's multiple  
996 comparison post-hoc test. ns=not significant, \*P ≤ 0.05, \*\*P ≤ 0.01, \*\*\*\*P ≤ 0.0001.

997

998 **Sup. Figure 8: GFP-COMMD2 vs. GFP volcano plot.** Mass-spectrometry interactome (n=2 biological  
999 replicates per condition) of immunoprecipitated GFP-COMMD2 from a stable A549 GFP-COMMD2 cell  
1000 line (1x10<sup>7</sup> cells total) or GFP A549 cell line control (1x10<sup>7</sup> cells total). Volcano plot of GFP-COMMD2  
1001 vs. GFP alone control. Identified interacting partners with known NF-κB p65 interaction in blue and  
1002 significant targets in yellow. Lines represent -log<sub>10</sub>(pV) and fold-change cutoffs with targets of  
1003 interested denoted.

1004

1005 **Sup. Figure 9: RNAi efficiency in primary nasal cells and Luminex analyte analysis of p62 RNAi.** A)  
1006 Representative immunoblot of RNAi conditions targeting COMMD2 or p62 in primary human nasal  
1007 epithelial cells from whole cell lysates at 48 hrs of RNAi. PVDF membrane probed for either COMMD2  
1008 or p62 protein levels. B & C) Quantification of COMMD2 and p62 protein levels post RNAi. Dot blot  
1009 with mean (bars) ± STD. One-way matched ANOVA with Dunnett's multiple comparison post-hoc test  
1010 comparing RNAi conditions to scrambled control. ns = not significant, \*\*P ≤ 0.01, \*\*\*P ≤ 0.001. D)  
1011 Secreted analytes (Luminex) at 4 hrs from Scr control in primary nasal cells (n=3 biological replicates)  
1012 challenged with either IL-1β (10 ng/ml), TIGR4 (MOI 20) ± IL-1β or 6B ST90 (MOI 20) ± IL-1β. E) Luminex  
1013 of secreted analytes at 4 hrs from RNAi p62 in primary nasal cells normalized to scrambled controls  
1014 (n=3 biological replicates). Cells were challenged with either IL-1β (10 ng/ml), TIGR4 (MOI 20) ± IL-1β  
1015 or 6B ST90 (MOI 20) ± IL-1β. Individual p values shown in comparison to respected Scr control.  
1016 Calculated by unpaired T. Test. Full details of analysis in Sup. Table 4.

1017

1018 **Sup. Figure 10: CMD2 nuclear translocation screen with pneumococcal mutants and hydrogen**  
1019 **peroxide.** A-C) Titration of hydrogen peroxide (A), purified Pneumolysin toxin (B), or their combination  
1020 (C) upon viability of the GFP-COMMD2 A549 stable cell line (n=4 biological replicates). Graphed as a  
1021 dot ± STD of biological replicates for IC<sub>50</sub> calculations by 4 parameter variable slope curve (red) with  
1022 IC<sub>50</sub> denoted in purple dashed line. Tabular comparison of IC<sub>50</sub>. D) Representative deconvolution  
1023 epifluorescence microscopy of A549 GFP-COMMD2 (gray) cells 2 hr post-challenge with either MOI 20  
1024 for each bacterial strain JW TIGR4 (wildtype), JW TIGR4 Δply W433F, TIGR4 (wildtype), TIGR4 ΔspxB or  
1025 TIGR4 ΔspxBΔply under titrated hydrogen peroxide treatment (0 – 6.25μM). E-F) Graphed as Dot blot  
1026 with mean (bars) ± STD. One-way matched ANOVA comparing selected columns with Bonferroni's  
1027 multiple comparison post-hoc test. ns = not significant, \*P ≤ 0.05, \*\*P ≤ 0.01, \*\*\*P ≤ 0.001, \*\*\*\*P ≤  
1028 0.0001. G) Inocula of intranasal mouse challenge shown as bar graph of mean ± STD. One-way ANOVA  
1029 comparing all means with Tukey's multiple comparison post-hoc test. ns=not significant, \*\*P ≤ 0.01.

1030 **References**


- 1031 1 Myszor, I. T. & Gudmundsson, G. H. Modulation of innate immunity in airway epithelium for  
1032 host-directed therapy. *Frontiers in immunology* **14** (2023).  
1033 <https://doi.org/10.3389/fimmu.2023.1197908>
- 1034 2 Hewitt, R. J. & Lloyd, C. M. Regulation of immune responses by the airway epithelial cell  
1035 landscape. *Nature Reviews Immunology* **21**, 347–362 (2021). [https://doi.org/10.1038/s41577-](https://doi.org/10.1038/s41577-020-00477-9)  
1036 [020-00477-9](https://doi.org/10.1038/s41577-020-00477-9)
- 1037 3 Connor, M. G. & Hamon, M. A. Advances in regulation of homeostasis through chromatin  
1038 modifications by airway commensals. *Current opinion in microbiology* **80**, 102505 (2024).  
1039 <https://doi.org/https://doi.org/10.1016/j.mib.2024.102505>
- 1040 4 Bosch, A. A., Biesbroek, G., Trzcinski, K., Sanders, E. A. & Bogaert, D. Viral and bacterial  
1041 interactions in the upper respiratory tract. *PLoS pathogens* **9**, e1003057 (2013).  
1042 <https://doi.org/10.1371/journal.ppat.1003057>
- 1043 5 Hakansson, A. P., Orihuela, C. J. & Bogaert, D. Bacterial-Host Interactions: Physiology and  
1044 Pathophysiology of Respiratory Infection. *Physiological reviews* **98**, 781–811 (2018).  
1045 <https://doi.org/10.1152/physrev.00040.2016>
- 1046 6 Connor, M. G. *et al.* The histone demethylase KDM6B fine-tunes the host response to  
1047 *Streptococcus pneumoniae*. *Nat Microbiol* **6**, 257–269 (2021).  
1048 <https://doi.org/10.1038/s41564-020-00805-8>
- 1049 7 Quinton, L. J. *et al.* Functions and regulation of NF-kappaB RelA during pneumococcal  
1050 pneumonia. *Journal of immunology (Baltimore, Md. : 1950)* **178**, 1896–1903 (2007).  
1051 <https://doi.org/10.4049/jimmunol.178.3.1896>
- 1052 8 Ferreira, D. M. *et al.* Controlled human infection and rechallenge with *Streptococcus*  
1053 *pneumoniae* reveals the protective efficacy of carriage in healthy adults. *American journal of*  
1054 *respiratory and critical care medicine* **187**, 855–864 (2013).  
1055 <https://doi.org/10.1164/rccm.201212-2277OC>
- 1056 9 Henriques-Normark, B. & Tuomanen, E. I. The Pneumococcus: Epidemiology, Microbiology,  
1057 and Pathogenesis. *Cold Spring Harbor perspectives in medicine* **3**, a010215 (2013).  
1058 <https://doi.org/10.1101/cshperspect.a010215>
- 1059 10 Jochems, S. P., Weiser, J. N., Malley, R. & Ferreira, D. M. The immunological mechanisms that  
1060 control pneumococcal carriage. *PLoS pathogens* **13**, e1006665–e1006665 (2017).  
1061 <https://doi.org/10.1371/journal.ppat.1006665>
- 1062 11 Robson, R. L., Reed, N. A. & Horvat, R. T. Differential activation of inflammatory pathways in  
1063 A549 type II pneumocytes by *Streptococcus pneumoniae* strains with different adherence  
1064 properties. *BMC Infect Dis* **6**, 71 (2006). <https://doi.org/10.1186/1471-2334-6-71>
- 1065 12 Weight, C. M. *et al.* Microinvasion by *Streptococcus pneumoniae* induces epithelial innate  
1066 immunity during colonisation at the human mucosal surface. *Nature communications* **10**,  
1067 3060 (2019). <https://doi.org/10.1038/s41467-019-11005-2>
- 1068 13 Ghosh, S. & Hayden, M. S. New regulators of NF-kappaB in inflammation. *Nature reviews.*  
1069 *Immunology* **8**, 837–848 (2008). <https://doi.org/10.1038/nri2423>
- 1070 14 Bhatt, D. & Ghosh, S. Regulation of the NF-kappaB-Mediated Transcription of Inflammatory  
1071 Genes. *Frontiers in immunology* **5**, 71 (2014). <https://doi.org/10.3389/fimmu.2014.00071>
- 1072 15 Rahman, M. M. & McFadden, G. Modulation of NF-κB signalling by microbial pathogens.  
1073 *Nature Reviews Microbiology* **9**, 291–306 (2011). <https://doi.org/10.1038/nrmicro2539>
- 1074 16 Johannessen, M., Askarian, F., Sangvik, M. & Sollid, J. E. Bacterial interference with canonical  
1075 NFκB signalling. *Microbiology (Reading, England)* **159**, 2001–2013 (2013).  
1076 <https://doi.org/10.1099/mic.0.069369-0>
- 1077 17 Brücher, B., Lang, F. & Jamall, I. NF-κB signaling and crosstalk during carcinogenesis. *4open* **2**,  
1078 1–35 (2019). <https://doi.org/10.1051/fopen/2019010>
- 1079 18 Hoffmann, A., Natoli, G. & Ghosh, G. Transcriptional regulation via the NF-κB signaling module.  
1080 *Oncogene* **25**, 6706–6716 (2006). <https://doi.org/10.1038/sj.onc.1209933>

- 1081 19 Basak, S. & Hoffmann, A. Crosstalk via the NF-kappaB signaling system. *Cytokine & growth*  
1082 *factor reviews* **19**, 187–197 (2008). <https://doi.org/10.1016/j.cytogfr.2008.04.005>
- 1083 20 Shih, V. F.-S., Tsui, R., Caldwell, A. & Hoffmann, A. A single NFkB system for both canonical and  
1084 non-canonical signaling. *Cell research* **21**, 86–102 (2011). <https://doi.org/10.1038/cr.2010.161>
- 1085 21 Huxford, T. & Ghosh, G. A structural guide to proteins of the NF-kappaB signaling module. *Cold*  
1086 *Spring Harbor perspectives in biology* **1**, a000075 (2009).  
1087 <https://doi.org/10.1101/cshperspect.a000075>
- 1088 22 Wong, D. *et al.* Extensive characterization of NF-κB binding uncovers non-canonical motifs and  
1089 advances the interpretation of genetic functional traits. *Genome biology* **12**, R70–R70 (2011).  
1090 <https://doi.org/10.1186/gb-2011-12-7-r70>
- 1091 23 Christian, F., Smith, E. L. & Carmody, R. J. The Regulation of NF-κB Subunits by  
1092 Phosphorylation. *Cells* **5**, 12 (2016). <https://doi.org/10.3390/cells5010012>
- 1093 24 Oeckinghaus, A. & Ghosh, S. The NF-κB Family of Transcription Factors and Its Regulation. *Cold*  
1094 *Spring Harbor perspectives in biology* **1**, a000034 (2009).  
1095 <https://doi.org/10.1101/cshperspect.a000034>
- 1096 25 Bartuzi, P., Hofker, M. H. & van de Sluis, B. Tuning NF-κB activity: A touch of COMMD proteins.  
1097 *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* **1832**, 2315–2321 (2013).  
1098 <https://doi.org/https://doi.org/10.1016/j.bbadis.2013.09.014>
- 1099 26 Newton, K. & Dixit, V. M. Signaling in innate immunity and inflammation. *Cold Spring Harbor*  
1100 *perspectives in biology* **4** (2012). <https://doi.org/10.1101/cshperspect.a006049>
- 1101 27 Burstein, E. *et al.* COMMD proteins, a novel family of structural and functional homologs of  
1102 MURR1. *The Journal of biological chemistry* **280**, 22222–22232 (2005).  
1103 <https://doi.org/10.1074/jbc.M501928200>
- 1104 28 de Bie, P. *et al.* Characterization of COMMD protein-protein interactions in NF-kappaB  
1105 signalling. *The Biochemical journal* **398**, 63–71 (2006). <https://doi.org/10.1042/BJ20051664>
- 1106 29 Maine, G. N., Mao, X., Komarck, C. M. & Burstein, E. COMMD1 promotes the ubiquitination of  
1107 NF-kappaB subunits through a cullin-containing ubiquitin ligase. *The EMBO journal* **26**, 436–  
1108 447 (2007). <https://doi.org/10.1038/sj.emboj.7601489>
- 1109 30 Maine, G. N. & Burstein, E. COMMD proteins and the control of the NF kappa B pathway. *Cell*  
1110 *Cycle* **6**, 672–676 (2007). <https://doi.org/10.4161/cc.6.6.3989>
- 1111 31 Maine, G. N. & Burstein, E. COMMD proteins: COMMing to the scene. *Cellular and molecular*  
1112 *life sciences : CMLS* **64**, 1997–2005 (2007). <https://doi.org/10.1007/s00018-007-7078-y>
- 1113 32 Riera-Romo, M. COMMD1: A Multifunctional Regulatory Protein. *Journal of cellular*  
1114 *biochemistry* **119**, 34–51 (2018). <https://doi.org/10.1002/jcb.26151>
- 1115 33 Geng, H., Wittwer, T., Dittrich-Breiholz, O., Kracht, M. & Schmitz, M. L. Phosphorylation of NF-  
1116 kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-  
1117 specific proteasomal elimination. *EMBO reports* **10**, 381–386 (2009).  
1118 <https://doi.org/10.1038/embor.2009.10>
- 1119 34 Thoms, H. C. *et al.* Nucleolar Targeting of RelA(p65) Is Regulated by COMMD1-Dependent  
1120 Ubiquitination. *Cancer research* **70**, 139–149 (2010). <https://doi.org/10.1158/0008-5472.Can-09-1397>
- 1121
- 1122 35 Mao, X. *et al.* COMMD1 (copper metabolism MURR1 domain-containing protein 1) regulates  
1123 Cullin RING ligases by preventing CAND1 (Cullin-associated Nedd8-dissociated protein 1)  
1124 binding. *The Journal of biological chemistry* **286**, 32355–32365 (2011).  
1125 <https://doi.org/10.1074/jbc.M111.278408>
- 1126 36 Kim, S. *et al.* Stress-induced NEDDylation promotes cytosolic protein aggregation through  
1127 HDAC6 in a p62-dependent manner. *iScience* **24**, 102146 (2021).  
1128 <https://doi.org/https://doi.org/10.1016/j.isci.2021.102146>
- 1129 37 Lamark, T. & Johansen, T. Aggrephagy: Selective Disposal of Protein Aggregates by  
1130 Macroautophagy. *International Journal of Cell Biology* **2012**, 736905 (2012).  
1131 <https://doi.org/10.1155/2012/736905>

- 1132 38 Svenning, S. & Johansen, T. Selective autophagy. *Essays in biochemistry* **55**, 79–92 (2013).  
1133 <https://doi.org/10.1042/bse0550079>
- 1134 39 Lobb, I. T. *et al.* A Role for the Autophagic Receptor, SQSTM1/p62, in Trafficking NF- $\kappa$ B/RelA  
1135 to Nucleolar Aggregates. *Molecular Cancer Research* **19**, 274 (2021).  
1136 <https://doi.org/10.1158/1541-7786.MCR-20-0336>
- 1137 40 Vonk, W. I. M. *et al.* The Copper Metabolism MURR1 Domain Protein 1 (COMMD1) Modulates  
1138 the Aggregation of Misfolded Protein Species in a Client-Specific Manner. *PLoS one* **9**, e92408  
1139 (2014). <https://doi.org/10.1371/journal.pone.0092408>
- 1140 41 Dong, W. *et al.* Streptococcus pneumoniae Infection Promotes Histone H3 Dephosphorylation  
1141 by Modulating Host PP1 Phosphatase. *Cell reports* **30**, 4016–4026.e4014 (2020).  
1142 <https://doi.org/https://doi.org/10.1016/j.celrep.2020.02.116>
- 1143 42 Muller, P. A. *et al.* Nuclear-cytosolic transport of COMMD1 regulates NF- $\kappa$ B and HIF-1  
1144 activity. *Traffic* **10**, 514–527 (2009). <https://doi.org/10.1111/j.1600-0854.2009.00892.x>
- 1145 43 Kudo, N. *et al.* Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a  
1146 cysteine residue in the central conserved region. *Proceedings of the National Academy of  
1147 Sciences of the United States of America* **96**, 9112–9117 (1999).  
1148 <https://doi.org/10.1073/pnas.96.16.9112>
- 1149 44 Singla, A. *et al.* Endosomal PI(3)P regulation by the COMMD/CCDC22/CCDC93 (CCC) complex  
1150 controls membrane protein recycling. *Nature communications* **10**, 4271 (2019).  
1151 <https://doi.org/10.1038/s41467-019-12221-6>
- 1152 45 You, G. *et al.* COMMD proteins function and their regulating roles in tumors. *Frontiers in  
1153 oncology* **13** (2023). <https://doi.org/10.3389/fonc.2023.1067234>
- 1154 46 Healy, M. D. *et al.* Structure of the endosomal Commander complex linked to Ritscher-Schinzel  
1155 syndrome. *Cell* **186**, 2219–2237.e2229 (2023). <https://doi.org/10.1016/j.cell.2023.04.003>
- 1156 47 Thomas-Chollier, M. *et al.* Transcription factor binding predictions using TRAP for the analysis  
1157 of ChIP-seq data and regulatory SNPs. *Nature protocols* **6**, 1860–1869 (2011).  
1158 <https://doi.org/10.1038/nprot.2011.409>
- 1159 48 Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator.  
1160 *Genome research* **14**, 1188–1190 (2004). <https://doi.org/10.1101/gr.849004>
- 1161 49 Zafar, M. A., Wang, Y., Hamaguchi, S. & Weiser, J. N. Host-to-Host Transmission of  
1162 Streptococcus pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell host &  
1163 microbe* **21**, 73–83 (2017). <https://doi.org/10.1016/j.chom.2016.12.005>
- 1164 50 Rossjohn, J. *et al.* The molecular mechanism of pneumolysin, a virulence factor from  
1165 Streptococcus pneumoniae. *Journal of molecular biology* **284**, 449–461 (1998).  
1166 <https://doi.org/10.1006/jmbi.1998.2167>
- 1167 51 Bryant, J. C. *et al.* Pyruvate oxidase of Streptococcus pneumoniae contributes to pneumolysin  
1168 release. *BMC microbiology* **16**, 271 (2016). <https://doi.org/10.1186/s12866-016-0881-6>
- 1169 52 Gladstone, R. A. *et al.* International genomic definition of pneumococcal lineages, to  
1170 contextualise disease, antibiotic resistance and vaccine impact. *EBioMedicine* **43**, 338–346  
1171 (2019). <https://doi.org/10.1016/j.ebiom.2019.04.021>
- 1172 53 Das, T., Chen, Z., Hendriks, R. W. & Kool, M. A20/Tumor Necrosis Factor  $\alpha$ -Induced Protein 3  
1173 in Immune Cells Controls Development of Autoinflammation and Autoimmunity: Lessons from  
1174 Mouse Models. *Frontiers in immunology* **9** (2018).  
1175 <https://doi.org/10.3389/fimmu.2018.00104>
- 1176 54 Moreno, R., Sobotzik, J.-M., Schultz, C. & Schmitz, M. L. Specification of the NF- $\kappa$ B  
1177 transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of  
1178 IKK $\epsilon$ . *Nucleic acids research* **38**, 6029–6044 (2010). <https://doi.org/10.1093/nar/gkq439>
- 1179 55 Collins, P. E., Mitxitorena, I. & Carmody, R. J. The Ubiquitination of NF- $\kappa$ B Subunits in the  
1180 Control of Transcription. *Cells* **5**, 23 (2016). <https://doi.org/10.3390/cells5020023>




- 1181 56 Lanucara, F. *et al.* Dynamic phosphorylation of RelA on Ser42 and Ser45 in response to  
1182 TNF $\alpha$  stimulation regulates DNA binding and transcription. *Open Biol* **6** (2016).  
1183 <https://doi.org/10.1098/rsob.160055>
- 1184 57 Saccani, S., Pantano, S. & Natoli, G. p38-Dependent marking of inflammatory genes for  
1185 increased NF-kappa B recruitment. *Nature immunology* **3**, 69–75 (2002).  
1186 <https://doi.org/10.1038/ni748>
- 1187 58 Jefferies, J. M. *et al.* Identification of novel pneumolysin alleles from paediatric carriage  
1188 isolates of *Streptococcus pneumoniae*. *Journal of medical microbiology* **59**, 808–814 (2010).  
1189 <https://doi.org/10.1099/jmm.0.018663-0>
- 1190 59 Quinton, L. J. & Mizgerd, J. P. Dynamics of lung defense in pneumonia: resistance, resilience,  
1191 and remodeling. *Annual review of physiology* **77**, 407–430 (2015).  
1192 <https://doi.org/10.1146/annurev-physiol-021014-071937>
- 1193 60 Pechous, R. D. With Friends Like These: The Complex Role of Neutrophils in the Progression of  
1194 Severe Pneumonia. *Frontiers in cellular and infection microbiology* **7**, 160–160 (2017).  
1195 <https://doi.org/10.3389/fcimb.2017.00160>
- 1196 61 Liu, J. *et al.* Advanced Role of Neutrophils in Common Respiratory Diseases. *Journal of*  
1197 *immunology research* **2017**, 6710278 (2017). <https://doi.org/10.1155/2017/6710278>
- 1198 62 Craig, A., Mai, J., Cai, S. & Jeyaseelan, S. Neutrophil Recruitment to the Lungs during Bacterial  
1199 Pneumonia. *Infection and immunity* **77**, 568–575 (2009). [https://doi.org/10.1128/IAI.00832-](https://doi.org/10.1128/IAI.00832-08)  
1200 [08](https://doi.org/10.1128/IAI.00832-08)
- 1201 63 Pechous, R. D., Sivaraman, V., Stasulli, N. M. & Goldman, W. E. Pneumonic Plague: The Darker  
1202 Side of *Yersinia pestis*. *Trends in microbiology* (2015).  
1203 <https://doi.org/10.1016/j.tim.2015.11.008>
- 1204 64 Yamamoto, K. *et al.* Roles of lung epithelium in neutrophil recruitment during pneumococcal  
1205 pneumonia. *American journal of respiratory cell and molecular biology* **50**, 253–262 (2014).  
1206 <https://doi.org/10.1165/rcmb.2013-0114OC>
- 1207 65 Bou Ghanem, E. N. *et al.* Extracellular Adenosine Protects against *Streptococcus pneumoniae*  
1208 Lung Infection by Regulating Pulmonary Neutrophil Recruitment. *PLoS pathogens* **11**,  
1209 e1005126 (2015). <https://doi.org/10.1371/journal.ppat.1005126>
- 1210 66 Connor, M. G. *et al.* The histone demethylase KDM6B fine-tunes the host response to  
1211 *Streptococcus pneumoniae*. *Nature Microbiology* (2020). [https://doi.org/10.1038/s41564-](https://doi.org/10.1038/s41564-020-00805-8)  
1212 [020-00805-8](https://doi.org/10.1038/s41564-020-00805-8)
- 1213 67 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time  
1214 quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) Method. *Methods (San Diego, Calif.)* **25**, 402–  
1215 408 (2001). <https://doi.org/10.1006/meth.2001.1262>
- 1216 68 Nguyen, L. K., Cavadas, M. A. S., Kholodenko, B. N., Frank, T. D. & Cheong, A. Species  
1217 differential regulation of COX2 can be described by an NFkB-dependent logic AND gate.  
1218 *Cellular and molecular life sciences : CMLS* **72**, 2431–2443 (2015).  
1219 <https://doi.org/10.1007/s00018-015-1850-1>
- 1220 69 Huang, F., Spangler, J. R. & Huang, A. Y. In vivo cloning of up to 16 kb plasmids in *E. coli* is as  
1221 simple as PCR. *PLoS one* **12**, e0183974 (2017). <https://doi.org/10.1371/journal.pone.0183974>
- 1222 70 Watson, J. F. & García-Nafria, J. In vivo DNA assembly using common laboratory bacteria: A  
1223 re-emerging tool to simplify molecular cloning. *The Journal of biological chemistry* **294**,  
1224 15271–15281 (2019). <https://doi.org/10.1074/jbc.REV119.009109>
- 1225 71 Thuring, R. W., Sanders, J. P. & Borst, P. A freeze-squeeze method for recovering long DNA  
1226 from agarose gels. *Analytical biochemistry* **66**, 213–220 (1975). [https://doi.org/10.1016/0003-](https://doi.org/10.1016/0003-2697(75)90739-3)  
1227 [2697\(75\)90739-3](https://doi.org/10.1016/0003-2697(75)90739-3)
- 1228 72 Tautz, D. & Renz, M. An optimized freeze-squeeze method for the recovery of DNA fragments  
1229 from agarose gels. *Analytical biochemistry* **132**, 14–19 (1983). [https://doi.org/10.1016/0003-](https://doi.org/10.1016/0003-2697(83)90419-0)  
1230 [2697\(83\)90419-0](https://doi.org/10.1016/0003-2697(83)90419-0)

- 1231 73 Jin, Z. *et al.* The hyperactive Sleeping Beauty transposase SB100X improves the genetic  
1232 modification of T cells to express a chimeric antigen receptor. *Gene therapy* **18**, 849–856  
1233 (2011). <https://doi.org/10.1038/gt.2011.40>
- 1234 74 Kowarz, E., Loscher, D. & Marschalek, R. Optimized Sleeping Beauty transposons rapidly  
1235 generate stable transgenic cell lines. *Biotechnology journal* **10**, 647–653 (2015).  
1236 <https://doi.org/10.1002/biot.201400821>
- 1237 75 Laemmli, U. K. Cleavage of Structural Proteins during the Assembly of the Head of  
1238 Bacteriophage T4. *Nature* **227**, 680–685 (1970). <https://doi.org/10.1038/227680a0>
- 1239 76 Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nature methods*  
1240 **9**, 676–682 (2012). <https://doi.org/10.1038/nmeth.2019>
- 1241 77 Kamentsky, L. *et al.* Improved structure, function and compatibility for CellProfiler: modular  
1242 high-throughput image analysis software. *Bioinformatics (Oxford, England)* **27**, 1179–1180  
1243 (2011). <https://doi.org/10.1093/bioinformatics/btr095>
- 1244 78 McQuin, C. *et al.* CellProfiler 3.0: Next-generation image processing for biology. *PLoS biology*  
1245 **16**, e2005970 (2018). <https://doi.org/10.1371/journal.pbio.2005970>
- 1246 79 Stirling, D. R., Carpenter, A. E. & Cimini, B. A. CellProfiler Analyst 3.0: accessible data  
1247 exploration and machine learning for image analysis. *Bioinformatics (Oxford, England)* **37**,  
1248 3992–3994 (2021). <https://doi.org/10.1093/bioinformatics/btab634>
- 1249 80 Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated proteomic-  
1250 sample processing applied to copy-number estimation in eukaryotic cells. *Nature methods* **11**,  
1251 319–324 (2014). <https://doi.org/10.1038/nmeth.2834>
- 1252 81 Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-  
1253 based shotgun proteomics. *Nature protocols* **11**, 2301–2319 (2016).  
1254 <https://doi.org/10.1038/nprot.2016.136>
- 1255 82 Olivella, R. *et al.* QCloud2: An Improved Cloud-based Quality-Control System for Mass-  
1256 Spectrometry-based Proteomics Laboratories. *Journal of proteome research* **20**, 2010–2013  
1257 (2021). <https://doi.org/10.1021/acs.jproteome.0c00853>
- 1258 83 Wiczorek, S. *et al.* DAPAR & ProStaR: software to perform statistical analyses in quantitative  
1259 discovery proteomics. *Bioinformatics (Oxford, England)* **33**, 135–136 (2017).  
1260 <https://doi.org/10.1093/bioinformatics/btw580>
- 1261 84 Pounds, S. & Cheng, C. Robust estimation of the false discovery rate. *Bioinformatics (Oxford,*  
1262 *England)* **22**, 1979–1987 (2006). <https://doi.org/10.1093/bioinformatics/btl328>
- 1263 85 Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression  
1264 in microarray experiments. *Statistical applications in genetics and molecular biology* **3**,  
1265 Article3 (2004). <https://doi.org/10.2202/1544-6115.1027>
- 1266 86 Gai Gianetto, Q. *et al.* Calibration plot for proteomics: A graphical tool to visually check the  
1267 assumptions underlying FDR control in quantitative experiments. *Proteomics* **16**, 29–32  
1268 (2016). <https://doi.org/10.1002/pmic.201500189>
- 1269



**B**

| Summary of unique proteins to uninfected GFP - control |               |
|--|---------------|
| 6B ST90 up   | 709 proteins  |
| 6B ST90 down   | 403 proteins  |
| TIGR4 up   | 1120 proteins |
| TIGR4 down   | 874 proteins  |





**F**


TIGR4 vs. 6B ST90 positive enrichment


| STRING GO Ontology (Biological Process) |  |          |         |
|---|--|----------|---------|
| #term ID                                | Term Description   | strength | FDR     |
| GO:1905337                              | Positive regulation of aggrephagy  | 1.63     | 0.0162  |
| GO:1905821                              | Positive regulation of chromosome condensation                           | 1.41     | 0.0341  |
| GO:0007091                              | Metaphase/anaphase transition of mitotic cell cycle                      | 1.33     | 0.0097  |
| GO:1902966                              | Positive regulation of protein localization to early endosome            | 1.33     | 0.0097  |
| GO:2000643                              | Positive regulation of early endosome to late endosome transport         | 1.33     | 0.0097  |
| GO:0090522                              | Vesicle tethering involved in exocytosis                                 | 1.28     | 0.0123  |
| GO:0033147                              | Negative regulation of intracellular estrogen receptor signaling pathway | 1.24     | 0.00081 |
| GO:0048194                              | Golgi vesicle budding  | 1.24     | 0.0162  |
| GO:0010968                              | Regulation of microtubule nucleation                                     | 1.19     | 0.02    |
| GO:0051469                              | Vesicle fusion with vacuole  | 1.19     | 0.02    |


A




B














A










A549 GFP-COMMD2 cells


**A**





**B**












**A**




**B**




**C**




**D**



**E**




**F**



| Summary proteins to uninfected GFP - control |        |             |                    |
|--|--------|-------------|--------------------|
|  | Unique | Significant | in p65 interactome |
| TIGR4  | 254    | 454         | 92                 |
| 6B ST90                                      | 49     | 249         | 59                 |
| IL-1 $\beta$                                 | 3      | 13          | NA                 |


**A**

Uninfected GFP-COMMD2 vs Uninfected GFP.




A


Primary human nasal cells



B




C




D


NF- $\kappa$ B motif prediction




E







NF- $\kappa$ B motif predicted sequence alignment





Primary human nasal cells





| Holm-Šidák's multiple comparisons test | Summary | Adj. P Value |
|--|---------|--------------|
| TIGR4 vs. 6B ST138 (high)              | ns      | 0.8741       |
| TIGR4 vs. 6B ST183 (low)               | **      | 0.0099       |

